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Molecular Recognition At Dna Damage Sites
Abstract
BRCA1 is frequently mutated in breast and ovarian cancer patients and it exerts its tumor suppressive
function within several distinctive complexes by facilitating error-free DNA repair via homologous
recombination (HR) mechanism. The particular focus of this dissertation is the BRCA1-RAP80 ubiquitin
recognition complex, which is composed of five core constituents (RAP80, Abraxas, MERIT40, BRCC45,
and BRCC36) and targets BRCA1 to the chromatin flanking DNA damage sites. Although this complex is
required for BRCA1 chromatin localization, its physiologic role has remained enigmatic, as has its
relationship to canonical DNA repair mechanisms. Here we show that Merit40 (scaffolding protein of the
RAP80 complex) deficient mice displayed marked hypersensitivity to DNA inter-strand crosslinks (ICLs),
but not to whole body irradiation. Instead, Merit40 mutation exacerbated ICL induced chromosome
instability in the context of concomitant Brca2 deficiency. These findings define specific functional
interactions between the RAP80 complex dependent ubiquitin recognition and the FA-BRCA ICL repair
network. As destabilization of the RAP80 complex is well tolerated in mice and could sensitive Brca2
mutant cells to frequently used chemotherapeutic agent mitomycin C (ICL-inducing agent), manipulating
this complex might allow selective killing of Brca2 cancer cells. Moreover, inhibiting the enzymatic activity
of the complex member BRCC36 was able to recapitulate Merit40 deficiency in cells and cause increased
lethality in Brca2 mutant mice, indicating the RAP80 complex mediates ICL repair via the deubiquitinating
(DUB) enzymatic activity of BRCC36. Mechanistically, we revealed that RAP80 is a substrate of BRCC36
and this deubiquitination process is essential to regulate the BRCA1-RAP80 chromatin localization.
Additionally, to understand the specific chromatin environment that recruits the RAP80 complex to DNA
damage sites, we devised a novel methodology to purify mono-nucleosomes bound by chromatin
associated DNA repair proteins and employed mass spectrometry to quantitatively measure the
abundance of individual post-translational modifications on these nucleosomes. This study allows us to
assess the full spectrum of chromatin modifications that associate with different DNA repair pathways,
and thus to direct DNA repair pathways by manipulating enzymes that are responsible for these
modifications.
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ABSTRACT
MOLECULAR RECOGNITION AT DNA DAMAGE SITES
Qinqin Jiang
Roger A. Greenberg
BRCA1 is frequently mutated in breast and ovarian cancer patients and it exerts its tumor
suppressive function within several distinctive complexes by facilitating error-free DNA
repair via homologous recombination (HR) mechanism. The particular focus of this
dissertation is the BRCA1-RAP80 ubiquitin recognition complex, which is composed of
five core constituents (RAP80, Abraxas, MERIT40, BRCC45, and BRCC36) and targets
BRCA1 to the chromatin flanking DNA damage sites. Although this complex is required
for BRCA1 chromatin localization, its physiologic role has remained enigmatic, as has its
relationship to canonical DNA repair mechanisms. Here we show that Merit40
(scaffolding protein of the RAP80 complex) deficient mice displayed marked
hypersensitivity to DNA inter-strand crosslinks (ICLs), but not to whole body irradiation.
Instead, Merit40 mutation exacerbated ICL induced chromosome instability in the
context of concomitant Brca2 deficiency. These findings define specific functional
interactions between the RAP80 complex dependent ubiquitin recognition and the FABRCA ICL repair network. As destabilization of the RAP80 complex is well tolerated in
mice and could sensitive Brca2 mutant cells to frequently used chemotherapeutic agent
mitomycin C (ICL-inducing agent), manipulating this complex might allow selective
killing of Brca2 cancer cells. Moreover, inhibiting the enzymatic activity of the complex
iv

member BRCC36 was able to recapitulate Merit40 deficiency in cells and cause
increased lethality in Brca2 mutant mice, indicating the RAP80 complex mediates ICL
repair via the deubiquitinating (DUB) enzymatic activity of BRCC36. Mechanistically,
we revealed that RAP80 is a substrate of BRCC36 and this deubiquitination process is
essential to regulate the BRCA1-RAP80 chromatin localization. Additionally, to
understand the specific chromatin environment that recruits the RAP80 complex to DNA
damage sites, we devised a novel methodology to purify mono-nucleosomes bound by
chromatin associated DNA repair proteins and employed mass spectrometry to
quantitatively measure the abundance of individual post-translational modifications on
these nucleosomes. This study allows us to assess the full spectrum of chromatin
modifications that associate with different DNA repair pathways, and thus to direct DNA
repair pathways by manipulating enzymes that are responsible for these modifications.
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CHAPTER 1. INTRODUCTION
Part of this chapter was published in the Journal of Biological Chemistry1.

I.

Homologous Recombination Preserves Genome Integrity

Thousands of DNA lesions occur daily due to constant exposure to DNA damaging
agents. A variety of DNA damage could either be generated during endogenous
metabolic process and DNA replication, or induced by environmental genotoxins, such as
ionizing radiation (IR) and ultraviolet (UV). Multiple forms of DNA damage occur
frequently in cells, including DNA base damage, DNA single-stranded breaks (SSBs),
DNA double-stranded breaks (DSBs) and DNA crosslinks. DNA base damage and SSBs
are less severe as the genetic information stored on the complementary strand is available
to ensure error-free DNA repair. Conversely, the mutagenic potential of DSBs and DNA
crosslinks could lead to genome rearrangement and many pathological consequences,
including cancers, therefore, faithful repair of these two types of lesions is particularly
important for genome stability. To carry out high-fidelity repair of both DSBs and DNA
crosslinks, cells have evolved an essential DNA repair mechanism, homologous
recombination (HR).

HR is an evolutionarily conserved mechanism that uses a homologous sequence, typically
a sister chromatid, as a template to ensure high-fidelity DNA repair. One of the critical
early steps in HR is 5’ to 3’ nucleolytic end resection that generates 3’ single-stranded
1

DNA (ssDNA) overhangs, which are bound by ssDNA binding protein, RPA. BRCA1
and BRCA2 (Breast Cancer Genes 1 and 2) proteins facilitate replacement of RPA by
RAD51. RAD51 coated ssDNA then initiates a search for homologous sequences on the
sister chromatid2. Due to the reliance on the sister chromatid, HR-mediated DNA repair
is largely restricted to S and G2 phases of the cell cycle when the sister chromatid is
present following the complete genome replication3-5.

The importance of HR has also been reflected in the pathology of human diseases.
Mutations in proteins that are essential for HR have high prevalence in breast and ovarian
cancers, indicating the important tumor suppressive role of HR mechanism. Up to 25% of
inherited breast cancers can be attributed to mutations in the Brca1 and Brca2 genes.
Women with inactivating mutations in the Brca1 tumor suppressor gene have up to 85%
risk of developing breast cancer in their lifetime6 and the cumulative risk of breast cancer
with Brca2 mutation was estimated to be 79.5% by age 707. A recent study has shown
that 51% of the primary tumors of a cohort of ovarian cancer patients harbored
inactivating mutations in HR repair factors8, again highlighting the essential role of HR
machinery in genome stability maintenance and tumor suppression. Furthermore,
germline mutations to both copies of a network of DNA repair genes—including
BRCA1, BRCA2, and other HR proteins—result in hypersensitivity to DNA crosslinks,
characteristic developmental anomalies, and cancer susceptibility9-14. This multiple
syndrome disease with aforesaid symptoms is called Fanconi Anemia (FA). This disease
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and the repair pathway specific for DNA crosslinks will be discussed in detail in the
section IV of the chapter.

II.

BRCA1 Tumor Suppressive Network

BRCA1 exerts its tumor suppressive function as part of at least four mutually exclusive
biochemical protein complexes15, which are essential for specific steps of HR or cell
cycle checkpoints. These complexes include BRCA1-PALB2-BRCA2, BRCA1-BRIP1,
BRCA1-CtIP and BRCA1-RAP80. BRCA1-PALB2-BRCA2 complex promotes RAD51
nucleofilament synthesis, thus initiates homology-directed repair16. The formation of the
other three complexes are dependent on the interaction of BRCT domain of BRCA1 with
a distinct phosphorylated protein, BRIP1, CtIP or Abraxas17,18. The BRCA1-BRIP1
complex contributes to S-phase checkpoint activity; the BRCA1-CtIP complex is
essential for DSB end resection; and the BRCA1-RAP80 complex (formed due to
interaction between BRCA1 and Abraxas) is responsible for BRCA1 localization to the
chromatin flanking DSBs and G2/M checkpoint signaling.

The RAP80-BRCA1 complex was discovered by the Greenberg lab and several other
groups, and is the focus of my dissertation. Germ-line mutations were identified in Rap80
and Abraxas in familial breast cancer, and numerous somatic mutations were observed in
all members of the complex19-21, indicating that BRCA1-RAP80 complex contributes to
tumor suppressive function of BRCA1.
3

The RAP80 complex, including RAP80, Abraxas, MERIT40, BRCC45, and BRCC36,
preferentially binds to lysine 63 (K63)-linked ubiquitin through the RAP80 tandem
ubiquitin-interacting motifs. The finding that BRCA1-RAP80 interaction is required for
focus formation of BRCA1 implicated non-degradative ubiquitin as a DNA damage
recognition platform during DSB signaling for the first time22-24. The important role of
ubiquitin signaling in DSB response will be discussed in greater detail in the section III
of this chapter. That loss of any member of the RAP80 complex eliminates observable
BRCA1 focus formation at DSBs, raises the question of whether the RAP80 complex
accounts for BRCA1 function in HR. Interestingly, Rap80 deficiency leads to hyperresection and increased sister chromatid exchanges in response to DSB-inducing agents,
indicating that the RAP80 complex is required to fine-tune HR efficiency by controlling
the resection level25,26. In contrast to the embryonic lethality of Brca1 knock-out mice,
Rap80, Abraxas, Merit40 or Brcc36 knock-out mice are viable and do not exhibit
apparent

developmental

defects19,27-29.

Additional

evidence

by

chromatin

immunoprecipitation (ChIP) suggests that RAP80 targets BRCA1 to chromatin regions
that are ~1 kb from break sites and affects checkpoint responses, but not DSB repair30.
Despite this relatively mild DNA repair phenotype, Rap80 and Abraxas knock-out mice
are tumor-prone, with ~20% of mice developing lymphomas within a year of birth19,28,29.
These observations indicate that RAP80 complex have tumor suppressive function.

4

III.

Ubiquitin and the DNA Damage Response

Chromatin localization of BRCA1 to DSBs is largely dependent on one specific type of
modification—ubiquitination. Ubiquitin is a 76-residue protein that can be added as a
post-translational modification to proteins to change their stability, localization, and
conformation, and thus regulates essential cellular processes, such as protein degradation,
transcription and DNA repair.

Ubiquitination occurs through three-step enzymatic reactions. First, an ubiquitinactivating enzyme (E1) utilizes ATP to activate ubiquitin. The activated ubiquitin is then
transferred to an ubiquitin-conjugating enzyme (E2) and a covalent thioester bond forms
between the E2 and the ubiquitin. Finally, an ubiquitin ligase (E3), coupled with the E2
enzyme, transfers the ubiquitin to its target protein. Substrate specificity is largely
determined by more than 600 different E3 ubiquitin ligases encoded by the human
genome31. Ubiquitin E3 ligases are divided into two groups. They either contain a RING
(Really Interesting New Gene) domain or a HECT (Homologous to E6AP Carboxy
Terminus) domain. The major difference between these two groups of E3 ligases is that
RING domain containing E3 enzymes facilitate interactions between E2s and substrate
proteins, but have no intrinsic ligase activities. In contrast, HECT domain containing E3
enzymes covalently bind to ubiquitin to form an intermediate, and then facilitate their
transfer to the target protein lysine residue. After the three-step signaling cascade, a
single ubiquitin moiety is added to a protein through covalent binding between the C5

terminal glycine of the ubiquitin and the primary amine of the ε-amino group of a lysine
substrate on a protein. A protein can be modified by multiple mono-ubiquitin moieties at
different lysine residues or poly-ubiquitination chains at a single lysine residue. There are
seven lysine residues (lysine 6, 11, 27, 29, 33, 48 and 63) on the ubiquitin protein and
these can all be modified by ubiquitin to generate poly-ubiquitination chains with
different topologies and thus lead to various biological outcomes. For example, lysine
48(K48)-linked poly-ubiquitination is added onto a protein to target it to proteasome for
degradation, while K63-linked poly-ubiquitinated proteins is mostly implicated in
signaling processes.

Protein ubiquitination is a reversible process and the removal or editing of ubiquitination
chains is mediated by deubiquitinating enzymes (DUBs). There are approximately 95
DUBs, which are categorized into five subclasses: ubiquitin C-terminal hydrolases
(UCHs), ubiquitin-specific proteases (USP2), Machado-Joseph domain-containing
proteins

(MJDs),

Otubain

domain-containing

proteases

(OTUs),

and

JAMM

(JAB1/MPN/Mov34) proteases32-34. DUBs have discriminating activities towards both
substrates and the linkage of the ubiquitin chains, and they play critical roles in ubiquitin
recycling and ubiquitin homeostasis maintenance. Together with E3 ubiquitin ligases,
DUBs can regulate the length and topology of ubiquitin chains and thus control crucial
cellular processes, one example of which is DNA damage response.

6

In response to DSBs, ubiquitination occurs as a result of a γH2AX-initiated signaling
cascade that recruits an E3 ligase RNF8. RNF8 mediated H1 ubiquitination act as a
docking site to localize RNF168, allowing it to perform large-scale DSB chromatin
ubiquitination at K13 and K15 sites on H2A/X35. Several DDR proteins rely on RNF168
E3 activity for DSB localization, including 53BP1, which is a specific reader of the H2A
K15-Ub mark36. The RAP80 complex specifically deubiquitinates the K63-Ub chains
through the actions of its associated Zn2+-dependent DUB, BRCC36. Unresolved
questions remain as to whether deubiquitinating enzyme activity serves to terminate
DNA damage association by removing the K63-ubiquitin recognition signal for RAP80
or, alternatively, in a ubiquitin-editing capacity, whereby it removes K63-linked
ubiquitin, thus allowing accumulation of either mono-ubiquitin or other ubiquitin
topologies that have been reported at DSBs37.

IV.

Inter-strand Crosslink Repair and Fanconi Anemia

Ubiquitination is not only essential for DSB repair, but also for another form of DNA
damage, DNA inter-strand crosslinks (ICLs). ICLs are a severe form of DNA crosslinks,
which effectively inhibit the separation of the DNA double helix, thus affecting essential
DNA activities, including replication and transcription. In cells, ICLs occur largely due to
exposure to metabolic by-products, such as aldehydes. ICLs can also be induced by a
variety of chemicals that are used as chemotherapy drugs for instance, cisplatin and
mitomycin C (MMC).
7

ICLs can be repaired by several mechanisms in different phases of the cell cycle. In our
studies, ICL-inducing chemotherapeutic drugs, MMC and psoralen are used to create
small distortions in the DNA double helix structure. These ICLs are primarily repaired in
S phase when replication forks encounter them on both sides of the lesions. Canonical
models have shown that replication fork convergence on FANCD2-I-bound ICL lesions
leads to cross-link incision and DSB formation. Then translesion synthesis machineries
coupled to BRCA2–RAD51-mediated HR repair of the resultant DSB lead to full
resolution of ICLs and restart of replication fork. Single-molecule imaging approaches
have revealed the existence of an ICL bypass mechanism that relies on FANCM to
translocate replication forks beyond psoralen cross-links38. Proposed mechanisms
underlying this genetic interaction invoke fork reversal and template switch-mediated
ICL bypass, indicating that mammalian cells might use other mechanisms of crosslink
response. These observations suggest several alternative possibilities for ICL repair. The
complexity within the ICL repair network is further highlighted by the overlapping yet
variable phenotypes observed in patients with mutations in different genes in this repair
pathway39,40.

Patients with ICL repair deficiency demonstrate sensitivity to endogenous aldehydes41
and develop a disease known as Fanconi Anemia (FA). FA is a rare hereditary syndrome
characterized by developmental defects, progressive bone marrow failure, and cancer
8

susceptibility. In contrast to heterozygous mutations that cause hereditary breast and
ovarian cancer, FA requires biallelic mutations within a network of at least 21 genes
dedicated to ICL repair. Mutations within several members of the BRCA1 network are
causative for FA. More recently, two patients have been identified with missense
mutations (R1699W and V1736A) within the first BRCA1 BRCT domain and a FA-link
syndrome, establishing BRCA1 as a Fanconi gene (FANCS) and highlighting the
importance of HR proteins in repairing ICLs13,14. While great efforts have been made in
understanding the genetic and pathophysiological mechanisms of FA in the past few
decades, medical treatments have remained challenging. The standard treatment for FA
patients is blood and marrow stem cell transplant, which could alleviate anemia, but not
manage other symptoms well. Therefore, better understanding of the ICL pathway is
critical in novel drug target identification for FA patients. My dissertation focuses on
understanding how the RAP80 complex mediates ICL repair pathway and how the DUB
activity of the RAP80 complex contributes to this repair process, which will be discussed
in Chapter 2 and 3 respectively.

V.

DNA Repair Pathway Choice

Mammalian cells have evolved several distinct pathways to coordinately repair DSBs,
including classical non-homologous end joining (C-NHEJ) and HR. HR, as an error-free
repair mechanism, is preferred over C-NHEJ to repair DNA replication associated
damage. The stepwise detail of the HR repair pathway has been discussed in the section I
9

of this chapter. On the other hand, repair by C-NHEJ, which involves ligation of two
broken ends together, occurs irrespective of the sequence flanking the DNA damage site,
and thus is error-prone. When repairing DSBs via C-NHEJ, minimal processing of the
breakage site is needed. Blunt or near-blunt ends of the DSBs will first be detected and
bound by the Ku70/80 heterodimer, then stabilized and aligned by DNA-dependent
protein kinase catalytic subunit DNA-PKcs, which signals and recruits downstream
effector proteins. DNA ligase IV is responsible for sealing the break and resolving the
DSBs. As this mechanism requires no sequence homology around the DSBs, C-NHEJ
could occur throughout the cell cycle, in contrast to that HR only functions in S/G2 phase
of the cell cycle when a sister chromatid homologous template is available. While CNHEJ is mutagenic, its fast kinetics prevents prolonged chromosomal breakage that could
potentially generate gross chromosomal translocations, and thus is crucial for genome
stability maintenance.

Many essential DNA repair proteins are involved in regulating the balance between the
two repair pathways, among which 53BP1 and BRCA1 act as two key master regulators
that mediate DNA repair pathway choice. The choice between HR and NHEJ is largely
dependent on DSB end resection level and cell cycle phase. End resection by the
structure-specific nuclease MRE11 and CtIP makes ends both available for homologybased repair mechanism, and inhibitory to C-NHEJ. Other than end resection level, cell
cycle phase also dictates pathway choice decision. In G1 phase of the cell cycle, 53BP1
and its effector proteins PTIP and RIF1 promote C-NHEJ by antagonizing BRCA1-CtIP
10

mediated end resection42-46. In contrast, extensive end resection is stimulated in S/G2 in a
manner dependent on CDK1-mediated CtIP phosphorylation47. Meanwhile, BRCA1-CtIP
counteracts 53BP1-RIF1, allowing these cells to perform end resection and downstream
signaling to carry out HR45. Recent genetic studies have further demonstrated the
antagonistic relationship between 53BP1 and BRCA1 mediated repair pathways. Brca1
mutant mice have defective HR and elevated 53BP1-dependent C-NHEJ leads to
genomic rearrangement and tumorigenesis. Remarkably, 53BP1 depletion ameliorates
most of the phenotypic abnormalities characteristic of Brca1 mutant mice, including
embryonic lethality, hypersensitivity to DNA damaging agents and HR deficiency48,49.
The underlying mechanism is that concomitant loss of 53BP1 in Brca1-deficient cells
allows for end resection and restores error-free repair by HR. Understanding the balance
between 53BP1 and BRCA1 signaling would not only provide mechanistic insights, but
also novel directions for therapeutic investigations. Canonically, patients with Brca1
mutations develop resistance to certain chemotherapeutic agents due to loss of 53BP1.
Therefore, increasing attention has been paid to gaining insight of repair pathway choice,
as shifting the balance between two repair pathways can be exploited to selectively kill
Brca1 deficient cells.

VI.

Chromatin Remodeling in Response to DNA Damage

Local chromatin environment contributes greatly to DNA repair pathway choice. In this
section, we will discuss how chromatin remodeling responds to DNA damage.
11

The basic function units of chromatin are nucleosomes, which are formed by wrapping
146 base pairs of DNA around a histone octamer that contains two H3-H4 dimers and
two H2A-H2B dimers. The function of nucleosomes is largely mediated by modifications
on the N-terminal of these core histone members. Common post-translational
modifications

(PTMs)

include

acetylation,

phosphorylation,

methylation

and

ubiquitination. These specific or combinatorial PTMs can either affect chromatin
compaction and alter local chromatin environment directly, or recruit chromatin
complexes to carry out particular functions. In response to DNA damage, ubiquitin E3
ligase RNF8 modifies linker histone H1, which acts as a docking site to recruit RNF168
to ubiquitinated H2A at K13/1535,50. Combined H2AK15 mono-ubiquitination and
H4K20 di-methylation recruit 53BP1 to DNA damage sites and channel DSB repair
through C-NHEJ repair pathway36,51. In contrast, acetylation at H4K16 antagonizes the
interaction between 53BP1 and H4K20Me2 and promotes chromatin relaxation and the
recruitment of BRCA1 and HR machineries52, indicating PTMs on histones affect local
chromatin environment, specific repair machinery recruitment, and thus repair pathway
choice53.

In summary, this dissertation focuses on understanding how the initial ubiquitin
recognition of DNA damage is essential for efficient DNA repair. We have employed
genetic mouse model, structural analysis as well as novel biochemical methodology to
12

understand three aspects of the process. Firstly, how RAP80-BRCA1 contributes to DNA
repair. Secondly, what the function of deubiquitinating enzyme (DUB) activity in DNA
repair process is. Lastly, how RAP80-BRCA1 competes with other chromatin associated
DNA repair factors to control genome stability.

13

CHAPTER 2. MERIT40 Cooperates with BRCA2 to Resolve DNA Interstrand
Cross-links
This chapter was published in the Genes and Development27.
I.

Introduction

Seminal insights into BRCA1 and BRCA2 function were revealed by their dynamic entry
into discrete RAD51 containing foci in response to DNA double-strand break (DSB)
formation54 and essential roles in homology directed repair. This physiologic role of
BRCA proteins and their interacting partners is phenotypically evident in the rare
hereditary developmental disorder Fanconi Anemia (FA). Germline mutations to both
copies of a network of DNA repair genes, including BRCA1, BRCA2, and several
associated proteins result in DNA inter-strand crosslink (ICL) hypersensitivity,
characteristic developmental anomalies, and cancer susceptibility9-11. In the case of
BRCA1, missense mutation within the BRCA1 C-terminal repeats (BRCT) disrupts
interaction with ICL repair proteins BRIP1/FANCJ and CtIP, and with the RAP80
ubiquitin recognition complex that targets BRCA1 to DNA damage foci, resulting in a
specific subtype of FA and extremely early onset breast and ovarian cancer13,14. This
syndrome appears to be less severe in BRCA1 BRCT mutants than in FA patients with
BRCA2 mutations. It is also noteworthy that BRCA1 BRCT mutant patients did not show
bone marrow failure, which is present in patients with mutations in most other FA
alleles13,14,55.

14

Large BRCA foci exist as a result of DSB-induced H2AX phosphorylation (γH2AX) and
ensuing recruitment of E3 ubiquitin ligases RNF8 and RNF168. Extensive RNF168dependent ubiquitination provides a recognition platform for DNA repair proteins that
span megabase stretches of chromatin surrounding DSBs35,56. The large BRCA1 foci
require interaction with the 5-member RAP80 complex (RAP80, Abraxas, MERIT40,
BRCC45, BRCC36). Tandem RAP80 ubiquitin interaction motifs (UIMs) display
specificity for non-proteasome directed lysine63-linked ubiquitin, as does the associated
deubiquitinating enzyme (DUB) BRCC3657. RAP80 also contains several SUMOinteracting motifs just amino terminal to the UIMs and displays approximately 80-fold
higher affinity for hybrid SUMO2,3-K63-ubiquitin chains suggesting that both ubiquitin
and SUMO chain recognition directs BRCA1-RAP80 complex foci formation58. Abraxas
directly binds to the BRCA1 BRCT repeats, and is also required for BRCC36 DUB
activity in vitro17,59. Less well-understood is MERIT40, which is not required for DUB
activity in vitro, but maintains interaction with the other subunits and is required for their
stability in cells and localization to DNA damage foci60-62. In contrast to BRCA1
nullizygosity, deficiency in either RAP80 or Abraxas is well-tolerated in mice19,28,63,
indicating that the most prominent component of DSB foci formation contributes to only
a subset of BRCA1 DNA repair function1.

Recent evidence suggests a physiologic role for the RAP80 ubiquitin recognition
complex in ICL repair. Abraxas null cells were sensitive to mitomycin C (MMC), and
this was associated with reduced homologous recombination19. BRCA1 has been reported
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to mediate several processes during ICL repair, where it functions in a HR-independent
manner to promote unloading of the replication initiating CMG complex during early
stages of ICL recognition64. BRCA1, in association with BRCA2 and RAD51, is also
thought to promote HR at ICL lesions that have undergone replication dependent
processing into DSBs. RAP80 is recruited during the initial stages of ICL recognition in
an ubiquitin dependent manner, possibly implicating its function in the BRCA1
dependent CMG clearance. This step in ICL repair is important for subsequent ICL
recognition by the FANCD2-I complex64.

Replication fork convergence on FANCD2-I bound ICL lesions leads to crosslink
incision and DSB formation following translesion synthesis, coupled to BRCA2-RAD51
homologous recombination repair of the resultant DSB. Evidence also exists in
mammalian cells for alternative mechanisms of crosslink responses. Single molecule
imaging approaches have revealed the existence of an ICL bypass mechanism that relies
on FANCM to translocate replication forks beyond psoralen crosslinks38. In addition, ICL
hypersensitivity of cells deficient in the canonical D2-I pathway can be circumvented by
reduced end resection as a result of DNA2 loss65. Proposed mechanisms underlying this
genetic interaction invoke fork reversal and template switch mediated ICL bypass. These
observations suggest several alternative possibilities for ICL repair, emphasizing
complexity within the FA-BRCA network that is further highlighted by the overlapping,
yet variable phenotypes observed in patients with mutations in different FA genes.
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This study uses Merit40 deficiency as a focal point to determine the importance of
ubiquitin recognition in the ICL recognition and repair process. Surprisingly, we reveal
unique positioning of MERIT40 within the FA-BRCA network at early stages of ICL
repair, thus distinguishing its interactions with FANCD2-I ICL recognition from
BRCA2-dependent HR. These studies further emphasize the nonlinear nature of ICL
recognition and repair, and indicate that ubiquitin recognition plays a distinct role from
canonical aspects of the FA-BRCA network.

II.

Merit40-deficient mice are hypersensitive to ICL agents

Merit40-/- mice were generated by gene trap insertion between exons 1 and 2, prior to the
start codon (Fig. S2-1A) as recently described66. Decreased transcript level of MERIT40
mRNA was detected across seven exons by RT-PCR (data not shown), and MERIT40
protein was undetectable in Merit40-/- MEFs, as determined by Western blotting (Fig. S21B). Merit40-/- mice were viable, fertile and did not display overt phenotypes in the
absence of exogenous genotoxic stress66

and this study

. However, as predicted by prior

studies60-62, Merit40-/- MEFs displayed reduced protein levels of binding partners and
proliferative rates, impaired G2/M checkpoint function, and loss of BRCA1 and RAP80
foci after ionizing radiation (IR) (Fig. 2-1A, B and S2-1C-F). Consistent with DNA repair
deficiency, increased spontaneous and persistent DSBs were observed in Merit40-/- MEFs
as measured by gH2AX foci (Fig. S2-1G, H).
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To investigate the physiologic contribution of MERIT40 to different forms of DNA
damage, Merit40-/- mice were exposed to IR, which creates DSBs in all cell cycle phases,
or to MMC, which produces ICL lesions that are primarily repaired in S-phase.
Surprisingly, no significant difference in mortality occurred between Merit40-/- and WT
littermate controls following 8.76Gy of IR (Fig. 2-1C), nor were Merit40-/- MEFs
hypersensitive to IR (Fig. 2-1D). Conversely, a highly significant (p=0.0027) increase in
mortality rate was observed following treatment with the ICL-inducing agent MMC in
Merit40-/- mice when compared to WT littermate controls (Fig. 2-1E). Similarly, Merit40/-

MEFs displayed increased sensitivity to MMC, as did U2OS cells following

knockdown of RAP80 complex members, MERIT40 or Abraxas (Fig. 2-1F, S2-2A).
Significantly higher numbers of chromatid breaks and radial chromosome structures were
also observed in Merit40-/- MEFs and in primary splenocytes (Fig. S2-2B, C), suggestive
of an ICL repair deficit. Consistent with impaired S-phase DNA repair, apoptotic rates
were elevated in Merit40-/- mice in highly proliferative organ systems 3 days post
intraperitoneal injection of MMC, but not in cardiac tissue, which largely exists in a postmitotic state (Fig. 2-1G, H, S2-2D, E). Together, these data highlight an important
physiologic role of MERIT40 in the repair of S-phase lesions in cycling cells.

To further examine the importance of MERIT40 in S phase DNA damage responses, WT
and Merit40-/- MEFs were labeled with BrdU, and then incubated for 1 hour with MMC
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or hydroxyurea (HU) to halt S-phase progression. Following removal of MMC or HU,
cells were chased with EdU to evaluate the ability of S phase cells (BrdU positive) to
restart replication67. Merit40-/- MEFs displayed significantly reduced recovery of DNA
replication in comparison to WT MEFs after HU or MMC treatment (Fig. 2-2A-C). A
similar phenotype was observed when using Aphidicolin (APH) to inhibit replication in
both WT and Merit40-/- MEFs as well as in MCF10A cells with knockdown of three
members of the RAP80 complex (Fig. S2-3A, B). We further investigated this
phenomenon using DNA fiber analysis to examine single replication track responses in
WT and Merit40-/- MEFs. In agreement with flow cytometry based results, Merit40-/MEFs displayed reduced replication restart efficiency upon transient replication blocks
from MMC or HU (Fig. 2-2D,E). Merit40-/- MEFs were more sensitive to cisplatin,
MMC, and PARP inhibitors (Fig. S2-3C-E), suggestive of a broad deficiency in
replication associated DNA damage responses. Despite the significant impairment in
replication restart, Merit40-/- MEFs displayed very mild sensitivity to HU, but significant
elevation in chromosomal abnormalities was observed in Merit40-/- MEFs post HU
treatment (Fig. S2-3F, G). This pattern of mild sensitivity and increased chromosome
aberrations is in agreement with prior results for Fanca mutant cells68.

In addition to its role as an essential member of the RAP80 complex, MERIT40 is critical
for the stability and function of the related BRISC deubiquitinating enzyme complex
(BRCC36 isopeptidase complex), which we have recently implicated in promoting
inflammatory cytokine receptor signaling69,70. KIAA0157 is a homolog to Abraxas and
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uniquely present in the BRISC complex. Kiaa0157-/- cells lose the BRISC complex while
retaining the nuclear RAP80 complex. Importantly, Kiaa0157-/- MEFs showed proper
recruitment of BRCA1 and RAP80 to IR induced foci and KIAA0157 knockout mice
were not sensitive to IR or MMC (Fig. S2-4). This indicates that MMC sensitivity in the
absence of MERIT40 was due to deficiency in the RAP80 complex, and not related to
deficiency in the BRISC complex.

III.

The RAP80 complex requires PARsylation and ubiquitylation for ICL
recognition

MERIT40 localizes to DSBs as a constituent of the RAP80 complex. DSB recognition
requires a phosphorylation to ubiquitylation signaling cascade initiated by MDC1
recognition of γH2AX and subsequent recruitment of E3 ubiquitin ligases RNF8 and
RNF168. To understand if similar requirements exist for ICL repair, MERIT40
localization was monitored at UV-induced psoralen crosslinks and at MMC-induced
crosslinks (Fig. 2-3A, S2-5A, B). The accumulation of MERIT40 at psoralen crosslinks
was abolished in HeLa cells upon deletion of RNF8 and RNF168 (Fig. 2-3A, B).
Additionally, deletion of the first UIM domain eliminated the accumulation of RAP80 at
psoralen crosslinks (Fig. 2-3C, D), confirming the importance of ubiquitin binding for
localization. RAP80-GFP recruitment was specific to ICL damage, as no recruitment was
observed without psoralen administration prior to laser activation (Fig. S2-5C).
Interestingly, the initial recruitment (within 30s) of RAP80 was not affected by depletion
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of RNF8 or RNF168, indicating that rapid accumulation of RAP80 depends on other
events (Fig. S2-5D, E). PAR-dependent mechanisms have been implicated in the rapid
localization of BRCA1 to DNA damage sites71, and RAP80 has recently been reported to
specifically bind PAR72. Indeed, either of the PARP inhibitors NU1025 or Olaparib
abrogated early phase GFP-RAP80 recruitment (<1min) to laser induced ICL damage
(Fig. 2-3E, F). These data indicate that MERIT40 is recruited to ICLs in association with
RAP80 in a biphasic manner. PARP activity is required for the initial recognition, while
ubiquitin binding mediates stable accumulation of the complex.

IV.

Merit40 deficiency reduces unhooking efficiency and homology directed
repair of ICL lesions

The preceding data suggests a specific role for MERIT40 in ICL repair. As the RAP80
complex is rapidly recruited to ICL sites, we asked whether RAP80 affects FANCD2
recruitment and downstream function. RAP80 accumulated at psoralen crosslinks at
approximately 1min, while FANCD2 required nearly 10min for maximal ICL
localization (Fig. 2-4A, B). Live cell imaging experiments confirmed that mcherryRAP80 ICL recruitment preceded that of GFP-FANCD2 (Fig. S2-6A, B). FANCD2
mono-ubiquitination is essential for localization subsequent to repair of ICLs. Despite the
faster ICL recruitment, knockdown of the RAP80 complex did not affect FANCD2
localization to ICL sites at 20min post UV activation of psoralen (Fig. S2-6C, D).
Additionally, splenocytes from WT and Merit40-/- mice did not show an obvious
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difference with respect to FANCD2 mono-ubiquitination at either 4 or 24 hours after
MMC (Fig. S2-6E).

The aforementioned results do not exclude the possibility that early recruitment of
MERIT40 to ICL damage is important in the initial phases of ICL processing. A modified
comet assay can be used to assess ICL unhooking efficiency in mammalian cells at the
single-cell level73-75. The presence of ICLs limits DNA migration into comet tails, leading
to decreased tail length. The degree of ICLs present was determined by comparing the
tail moment of irradiated, cisplatin-treated samples with irradiated samples that were not
treated with cisplatin (please see figure legend and methods for a detailed description).
The decrease in comet tail length peaked at 6h in WT MEFs, followed by a sustained
increase in length through 40h. The peak in comet tail length decrease occurred at 9h post
cisplatin treatment in Merit40-/- MEFs and remained delayed in comparison to WT MEFs
for 30h (Fig. 2-4C). These data reveal that loss of MERIT40 reduces the efficiency of
ICL unhooking and supports a functional importance to the rapid ICL recruitment of the
RAP80 complex.

To investigate subsequent steps in ICL repair, we investigated whether loss of MERIT40
affected HR efficiency and protein recruitment. Merit40-/- cells showed modestly reduced
sister chromatid exchange (SCE) after MMC treatment (Fig. 2-4D, S2-7A). MERIT40
knockdown was achieved by three different siRNAs in HeLa cells and the intensity of
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repair protein level was examined at psoralen crosslinks. The accumulation of BRCA1
and RAD51 was reduced upon MERIT40 knockdown (Fig. 2-4E, F, S2-7B, C).
Additionally, the mean intensity of RPA recruitment was reduced upon depletion of
MERIT40 at psoralen crosslinks (Fig. 2-4G, S2-7D) and Merit40-/- cells displayed
significantly reduced p-RPA level post MMC treatment (Fig. S2-7E). Similar reductions
in RPA and RAD51 at MMC-induced foci were also observed in U2OS cells following
MERIT40 knockdown (Fig. S2-7F, G). These results suggest that HR deficiency in
Merit40 null cells results from a cumulative reduction in end resection and RAD51
nucleofilament formation.

In contrast, several prior reports demonstrate that loss of RAP80 leads to increased end
resection and HR in response to nuclease or etoposide induced DSBs in human cancer
cell lines30,76. This could occur as a consequence of the RAP80 complex imparting a
differential impact on processing of DSBs in comparison to ICLs, or alternatively due to
differences between human cancer cell lines and primary mouse cells. Consistent with
prior data, we detected an approximately 30% increase in SCEs in Merit40-/- MEFs after
etoposide-induced DSBs (Fig. S2-7H). Furthermore, a 2.5 fold increase in single stranded
DNA (ssDNA) levels was observed in Merit40-/- splenocytes compared to WT
counterparts as measured by non-denaturing BrdU signal in S/G2 phase cells at 2 hours
after IR (Fig. S2-5I-K)77. These data reveal that loss of MERIT40 differentially affects
end resection at DSBs and ICL damage, and suggest unique contributions of the RAP80
complex to each repair process.
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V.

Merit40 deficiency does not exacerbate MMC sensitivity in Fancd2 null mice.

A genetic approach was undertaken to understand how ubiquitin recognition by the
RAP80 complex intersected with the major components of ICL repair. Merit40-/- mice
were bred to genetic backgrounds harboring mutations in the major arms of ICL repair,
Fancd2 or conditional Brca2 (floxed exon 11). MEF cell lines were established from
these crosses. Merit40, Fancd2 double knockout mice are viable and do not show
reduced body weight or other additional compromise in comparison to Fancd2 null mice.
Moreover, loss of MERIT40 did not affect sensitivity of Fancd2-/- MEFs to MMC (Fig.
2-5A). Additionally, Merit40-/- Fancd2-/- MEFs or splenocytes did not show significantly
different levels of chromosomal breaks or radial chromosomes in comparison to Fancd2-/MEF cells (Fig. 2-5B). RPA levels at psoralen crosslinks and SCEs in response to MMC
were also similar in Merit40-/- Fancd2-/- MEFs when compared to Fancd2-/- MEFs (Fig.
2-5C-E). However, while double knockout Merit40-/- Fancd2-/- splenocytes, did not show
significant differences in total chromosomal aberrations when compared to Fancd2-/cells, there was a trend towards increased chromosomal breaks and a significant
reduction in radial chromosomes occurred in the splenocytes of double knockouts (Fig.
S2-8A). These data suggest that MERIT40 and FANCD2 are not functionally redundant
during ICL repair.
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VI.

Cooperative interactions between MERIT40 and BRCA2 in response to
ICLs

Given the minimal genetic interaction between MERIT40 and FANCD2, we asked
whether MERIT40 would instead contribute in a more substantial manner to ICL repair
in the context of impairment in other aspects of the FA-BRCA ICL repair network.
Conditional deletion of BRCA2 was achieved in MEFs by 4-hydroxy tamoxifen (4-OHT)
induced activation of the CreERT2 fusion protein, which was constitutively expressed in
cells harboring a homozygous floxed BRCA2 exon11 allele. WT and Merit40-/- MEFs
expressing the CreERT2 fusion protein were used in all experiments to control for the
potential off-target Cre induced DNA damage78. Interestingly, the plating efficiency of
Merit40-/- Brca2-/- MEFs was significantly lower compared to MEFs harboring either
Merit40-/- or Brca2-/- in isolation (Fig. 2-6A, B). Combined Brca2 and Merit40 deficiency
demonstrated increased sensitivity to ICL damage as measured by elevated cytogenetic
aberrations in both MEFs and primary splenocytes (Fig. 2-6C, S2-9A-C). Merit40-/Brca2-/- cells showed a greater than additive increase in chromosomal breaks compared to
Merit40-/- or Brca2-/- in MEFs, while double knockout splenocytes showed an
approximately additive increase in chromosome aberrations compared to the single
knockouts. Moreover, knockdown of RAP80, MERIT40 or Abraxas in pancreatic
adenocarcinoma CAPAN-1 cells, which contain a truncated form of the BRCA2 protein,
resulted in an approximately 2-fold higher level of chromosomal aberrations compared to
control siRNA transfected cells (Fig. S2-9D). The data are consistent with the presence of
a strong genetic interaction in cells lacking MERIT40 and BRCA2 and suggest an
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enhanced requirement for BRCA2 in the absence of MERIT40. To understand the
mechanism of how MERIT40 and BRCA2 cooperate in response to ICLs, we examined
the HR efficiency by SCE analysis in response to MMC. A significantly reduced amount
of SCEs was observed in Merit40-/- Brca2-/- compared with Brca2-/- cells (Fig. 2-6D),
suggesting MERIT40 and BRCA2 work in part to coordinately promote HR in response
to ICL damage.

VII.

DNA2 differentially affects ICL repair in Merit40 and Fancd2 null cells

The preceding results reveal contrasting genetic interactions between MERIT40 and
canonical arms of the FA-BRCA ICL repair network, FANCD2 or BRCA2. These
observations necessitated additional investigations into whether MERIT40 and ubiquitin
recognition is functionally redundant with the FANCD2-I arm of ICL repair, or
alternatively, if it constitutes a distinct component of the ICL repair network. DNA2 was
previously shown to be responsible for over-resection in Fancd2-/- cells and knockdown
of DNA2 suppressed ICL hypersensitivity in Fancd2-/- cells65. Given that ICL
hypersensitivity was not increased in Merit40, Fancd2 double null cells, we asked
whether DNA2 knockdown would also restore ICL resistance in Merit40-/- cells. If
MERIT40 affects ICL repair in a common mechanism with FANCD2, a prediction is that
concomitant DNA2 deficiency would similarly impact ICL repair in either Fancd2 or
Merit40 null backgrounds. In agreement with previous reports65, DNA2 knockdown
reduced genomic instability in MMC treated Fancd2-/- cells (Fig. S2-8B, C). Conversely,
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transfection of two independent siRNAs targeting DNA2 strongly increased chromosome
aberrations in MMC treated in Merit40-/- cells and reduced cell survival in response to
MMC (Fig. 2-6E, S2-8D, S2-10A). These data reveal that MERIT40 and FANCD2
contributions to ICL repair can be differentiated by their genetic interaction with DNA2.

DNA2 knockdown also increased genomic instability in Merit40-/- Brca2-/- cells (Fig. 26E, S2-10A). Similar results were obtained following transfection of siRNA targeting
CtIP in double knockout cells and by Exo1 knockdown in Merit40-/- MEFs, consistent
with an increased requirement for end resection in MERIT40 null cells (Fig. S2-10B, C).
Comparable SCE numbers were observed before and after DNA2 knockdown in Merit40/-

Brca2-/- cells (Fig. 2-6F), suggesting that DNA2 dependent resection contributes to an

alternative, HR independent repair function in the context of dual deficiency for BRCA2
and MERIT40. Knockdown of essential MMEJ proteins Lig3 or POLQ did not
exacerbate chromosomal abnormalities (Fig. S2-10D-F) suggestive that other resection
dependent repair events are invoked in Merit40-/- Brca2-/- cells.

VIII.

Discussion

The physiologic importance of RAP80 complex ubiquitin foci association has remained
elusive despite considerable investigation into DNA damage recognition mechanisms and
its roles in cancer susceptibility19-21,79,80. This study reveals that a major function of the
RAP80 complex is in DNA replication associated repair. Surprisingly, in contrast to
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Rap80-/- and Abraxas-/- mice19,28,63, Merit40-/- mice or cells were not significantly
hypersensitive to IR even though they exhibited G2 checkpoint impairment. These issues
withstanding, Abraxas deficiency was also reported to confer MMC hypersensitivity19.
Our results are consistent with these published reports in that deficiency of multiple
RAP80 complex members showed similar deficits in ICL responses.

ICL hypersensitivity was associated with reduced ssDNA generation and homology
directed repair in Merit40-/- cells despite elevation of these DNA damage associated
markers in response to etoposide, IR, or nuclease induced breaks25,26,30. The opposing
reduction in ssDNA formation in response to ICL damage may be a consequence of
delayed ICL unhooking in Merit40-/- cells, consistent with involvement of MERIT40 in
the earliest stages of ICL recognition and processing.

Repair of lCL lesions in S-phase requires a multistep process that entails ICL recognition,
dual incisions on either side of the crosslink, DNA synthesis through the crosslink by
TLS polymerases and BRCA-RAD51 dependent HR repair of the ensuing DSB. The
ubiquitinated D2-I complex plays a critical role in early ICL recognition and processing
steps, whereas BRCA1 and BRCA2 have been implicated in both early and later aspects
of ICL repair. Our extensive genetic interaction data is supportive of epistasis between
MERIT40 and FANCD2. MERIT40 was required for timely ICL unhooking, and
importantly double knockout Merit40-/-, Fancd2-/- mice and cells did not show any
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phenotypic or ICL repair exacerbations beyond that of Fancd2 deficiency alone. In stark
contrast, Merit40-/- and Brca2-/- alleles produced at least additive increases in genomic
instability in response to MMC coupled with strongly reduced cell viability. However, we
posit that MERIT40 contributes to multiple aspects of ICL repair (Fig. 2-7) in a manner
that is not completely overlapping with FANCD2-I, thus accounting differences in its
genetic interactions with DNA2. These genetic interactions enhance our understanding of
the multifactorial response to ICL damage and suggest targeting MERIT40 or other
components of the RAP80 complex as an additional means to reduce viability in BRCA2
mutant cells.

IX.

Experimental Procedures

Mice: C57BL/6J (strain 000664) and B6(Cg)-TyrC-2J/J (strain 000058) were purchased
from the Jackson Laboratory. The homozygous conditional BRCA2tm1Brn mouse strain
(01XB9) was purchased from the NCI Mouse Repository. The Cre-ERT2 B6.CgTg(UBC-cre/ERT2)1EjB/J strain was generously provided by Dr. Eric J. Brown
(University of Pennsylvania, Philadelphia). The FancD2 knockout mouse was generously
provided by Dr. Alan D’Andrea (Dana-Farber Cancer Institute, Harvard Medical School).

Generation of MERIT40-/- mouse: MERIT40 (RIKEN cDNA 5430437P03 gene, MGI:
1915501) knock-out mice were generated by microinjecting an embryonic stem (ES) cell
clone provided by Texas A&M Institute for Genomic Medicine (IST11207B9) into
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C57BL/6 host mouse blastocysts. The MERIT40 locus was disrupted by insertion of the
Omnibank gene-trap vector 76 into the MERIT40 first intron, upstream from exon-2
containing the ATG translation start site as described in (Rozenova et al. 2015) and at
(http://www.tigm.org/). Chimeric mice were generated and bred to B6(Cg)-TyrC-2J/J and
black pups selected for genotyping. The resulting heterozygous mice were crossed to
generate Merit40-/- mice.

Genotyping: Genotyping was performed by PCR on genomic DNA isolated from mouse
tails by digestion overnight at 55°C in a lysis buffer containing 100 mM Tris pH 8.0, 5
mM EDTA, 0.2% SDS, 200 mM NaCl and 100 µg/mL proteinase K. DNA was
precipitated with isopropanol and washed 2 times with 70% ethanol before being resuspended in TE buffer, quantified and used for PCR reactions. The following primers
were mixed for genotyping: M40F: 5′-GGGAAACTTCAACTGTATCTTTTCGGCTCC3′, M40R: 5′-AAGACAGAAGATGGGCACGAGCCCCTTAC-3′, and V76R: 5′CTTGCAAAATGGCGTTACTTAAGC-3′. Primer pair M40F/M40R gave a band of 480
bp corresponding to the WT allele, PCR from primer pair M40F/V76R gave a band of
320 bp corresponding to the disrupted allele. PCR conditions do not allow formation of
the product corresponding to WT allele when containing the gene-trap vector.
Amplifications were performed using GoTaq green master mix (Promega) in a S1000
thermal cycler (Bio-Rad). BRCA1 11co/ 11co mice were genotyped according to the Mouse
Δ

Δ

Repository instructions.
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siRNA targets human MERIT40:
M40 C: 5’-CAGAGAACGUGCAGACGAUdTdT;
M40 D: 5’-GCUCUGUAGCUGCCUCUAUdTdT;
M40 E: 5’-GGAGAUGAGUUGGAAGGAUdTdT.
siRNAs targets mouse genome:
CtIP: UGUGAUCGCUGUGCAGUAAdTdT;
DNA2-1: GCAACAACGGUGUUUCGAUdTdT;
DNA2-2: CGGUACAAUUCUCCACGAAdTdT;
siExoI: GGAUGUACUCUACCUUCUAdTdT;
siLig3: GAGCUGGAAGAUAACGAAAdTdT;
siPOLQ: CCCAUCAAAUGUGAACGUAdTdT.
siRNA transfections were performed using Lipofectamine RNAiMax (Invitrogen)
according to manufacturer’s instructions, and cells were assayed 48 h after transfection.

G2/M checkpoint assay: The G2/M checkpoint assay was performed by assessing the
percentage of mitotic cells at 2 hours after irradiation with either 0 or 2 Gy. Cells were
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collected 2 hours later and processed for flow cytometry as previously described.
phosphorylated histone H3 (Upstate Biotechnology) was used to detect mitotic cells.

Irradiation: All radiation exposures were performed with a Gammacell 40 irradiator
(Nordion International), which uses cesium-137 as the radiation source.

Mouse survival assay: To assess radiosensitivity and mitomycin C sensitivity in vivo,
age-matched (between 6 and 12 weeks) WT and Merit40-/- littermates were subjected to
IR (8.76 Gy) or mitomycin C (12 mg/kg). MMC was re-suspended in PBS and injected
intraperitoneally. Mice were monitored daily to establish Kaplan–Meier curves. A logrank test was used for statistical analysis.

Clonogenic Survival Assay Cells were induced with 500nM 4-OHT for 48h and then
seeded in a 60 mm dish. The following day, cells were treated with MMC at the indicated
dose for 24 h. The drug was washed out, and cells were allowed to recover for 1-2 weeks.
Plates were stained with 0.5% crystal violet for 1h, and colonies were counted. Each
genotype and drug dose was done in triplicate in three independent experiments.

Cell Culture: All human cell lines and MEFs were maintained in DMEM (Invitrogen)
with 10% calf serum and penicillin and streptomycin. Rap80+/+ and Rap80-/- cell lines
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were provided by Dr. Junjie Chen (MD Anderson). MEFs were immortalized after
transfection with an shRNA directed against p19Arf. Splenocytes were maintained in
RPMI glutamax with Beta-mercaptethanol, 10% FBS, 1% sodium pyruvate, 1%
nonessential amino acid, 10ug/ml LPS.

Antibodies: A MERIT40 rabbit polyclonal antibody raised against mouse MERIT40 was
generated against a GST-MERIT40 fusion protein and used at 1:200 for IB and 1:100 for
IF as previously described 61. γH2AX (Millipore JBW301) was used at 1:2000 for IF and
1:1000 for IB. BRCA1 was detected by IF with a homemade rabbit polyclonal antibody
raised against the exon 11 region of mouse BRCA1 at 1:100. Homemade Rap80 rabbit
polyclonal antibody was used for IB at 1:500 and IF at 1:150. BRCC36 was detected for
IB with a rabbit polyclonal Ab {Sobhian:2007hp} at 1:1000. KIAA0157 was detected
with a rabbit polyclonal antibody (LSBio, LS-C102632) diluted at 1:1000

70

. Alpha-

tubulin (Cell signaling, DM1A, 1:10000) was used as a loading control on IB. p-RPA
(S4/S8) (Bethyl Laboratories A300-245a) was used for IB at 1:1000. Total RPA (Novus
NB600-565) was used for IB at 1:200. FANCD2 (Abcam, ab108928) was used of IB at
1:200. RPA32/RPA2 (Abcam, ab61184) was used for IF in mouse cells at 1:200.

Immunofluorescence: Cells were washed with PBS and pre-extracted in a buffer
containing 10 mM Pipes, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2 and 0.5% triton
X-100 for 5 minutes at 4°C or fixed directly in a solution containing 3%
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paraformaldehyde, 2% sucrose for 10 min at room temperature. Cells were subsequently
permeabilized with 0.5% Triton-X100, 50 mM Tris-HCl pH7.4, 150 mM NaCl, 5 mM
EDTA, 0.05% NP-40 and 0.25% gelatin IV for 10 minutes at 4°C and then incubated in a
blocking solution (10% goat serum diluted in PBST) prior to incubation with the
appropriate primary antibody for 1 hour at 37 °C. Cells were then washed with PBST and
next incubated with secondary antibody diluted in PBST for 20 min at 37 °C. After 3
washes with PBST, coverslips were mounted onto glass slides using Vectashield
mounting medium containing DAPI (Vector Laboratories) and visualized using a Nikon
Eclipse 80i fluorescent microscope.

Metaphase spreads: Cells were treated with 0.5 µM nocodazole for 3 h and swollen in 75
mM KCl for 25 minutes at 37°C. Cells were fixed on ice with a 3:1 methanol/acetic acid
solution. Metaphases were dropped onto slides pre-heated at 42°C, allowed to dry, and
stained with Giemsa. The numbers of sister chromatid breaks and chromosome breaks
per metaphase were counted. For sister chromatid exchange analysis, cells were
pretreated for 48 h with 10 mM BrdU and collected as above. After dropping metaphases
onto slides, they were stained with 10 mg/ml Hoechst 33258 in PBS for 20 min. The
slides were rinsed in McIlvaine solution for 10 min and treated with 365-nm UV for 30
min. Slides were incubated in 1× SSC at 55 °C for 1 h. Slides were then stained with
Giemsa and analyzed for the number of sister chromatid exchanges/chromosome.
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DNA Fiber Assay: Cells were labeled with IdU (50mM) or CldU (100 mM). DNA fibers
were spread as described 81 and stained with primary and fluorescent secondary antibody
(primary antibody: α-IdU: Becton Dickinson 347580; α-CldU: Abcam ab6326). Fibers
were imaged with a 60X objective and analyzed using ImageJ software.

Native BrdU detection: Exponentially growing splenocytes were pulsed with 1mM 5bromo-2’-deoxyuridine (BrdU, Sigma) for 30 hrs, irradiated (30Gy, 2hrs recovery at
37°C); then fiexed with 70% ethanol. Cells were blocked in 3% BSA in PBS for 30min,
then stained with anti-BrdU monoclononal antibody (Invitrogen Mobu-1 1:50) for 1h.
Before analysis, propidium iodide was added to a final concentration of 50mg/ml.

Modified alkaline Comet assay: Cells were treated with 50mM cisplatin for 1h. After
treatment, cells were either immediately harvested (0h) or incubated in fresh media
before harvesting at 4h, 6h, 7.5h, 9h, 17h, 40h post cisplatin wash off. Control cells were
not treated with cisplatin. Immediately before analysis, cells were irradiated (12.5Gy) to
get a fixed number of DNA strand breaks. We performed an alkaline comet assay based
on the protocol from CometAssay Kit (Trevigen, 42150-050-K). Olive Tail Moment was
obtained by using OpenComet plugin in ImageJ program. % decrease in Olive tail
moment=[1−(TMdi−TMcu)/(TMci−TMcu)]x100, where TMdi = tail moment of cisplatintreated irradiated sample; TMcu = tail moment of untreated, unirradiated control; TMci =
tail moment of untreated, irradiated control. % decrease in Olive tail moment at early
35

time point demonstrates peaks when ICLs in cells get unhooked.
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Figure 2-1. Merit40 deficient mice are hypersensitive to MMC, but not to IR.
(A) Representative images of MEFs of the indicated genotypes at 8h post IR. Scale Bar:
10mm.
(B) Quantification of foci number from (A). Error bars represent Standard Error of the
Mean (SEM). Significance was analyzed with two-tailed paired Student’s t test; *
P<0.05, ** P<0.01, *** P<0.001, ****P<0.0001.
(C) 6 to 12 week old WT and Merit40-/- (M40) littermates were subjected to 8.76 Gy IR.
Mice were monitored daily and survival rate was displayed as indicated.
(D) MEFs were treated with DNA-PK inhibitor (4mM) or DMSO for 1h before being
subjected to IR. DNA-PK inhibitor treated WT MEFs were used as a positive control.
Three independent experiments were conducted. Statistical analysis was performed
between WT, M40, and between WT, WT+PKi at the same IR dose.
(E) Mice were subjected to one-time intraperitoneal injection of 12mg/kg MMC and
survival for each genotype monitored as in (C).
(F) Merit40-/- MEFs displayed reduced survival to escalating doses of MMC as assessed
by clonogenic assay. Student’s t tests were performed between WT and M40 indicated
cell type at the same drug dose.
(G) Representative field of TUNEL staining in WT and M40 mice (×200). Scale Bar:
500mm
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(H) TUNEL positive cells were quantified by counting 4 fields per mouse and three mice
per genotype at Day 3 post MMC.
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Figure 2-2. MERIT40 mediates replication fork recovery in response to S phase
damage
(A) Schematic illustration replication fork restart experiments. Cells were pulsed with
BrdU for 30min before HU or MMC treatment to label cells that are in S phase; HU or
MMC was added for 1h to induce replication fork stalling, followed by EdU treatment for
1 hour to detect fork recovery for cells in S phase. BrdU+ cells were gated and further
analysis was performed on the population to detect EdU incorporation following
replication fork recovery.
(B) Representative image of replication fork restart. M40 cells have a lower rate of
replication fork restart.
(C) Quantification of (B) based on three independent experiments of HU or MMC
treatment.
(D) Representative image of single fiber analysis. Red Tracks, IdU; green tracks, CldU.
Example of a stalled fork and a restarted fork.
(E) Schematic depicts experiment design. Percentage of restarted forks equal number of
restarted forks divided by the sum of stalled forks and restarted forks.
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Figure 2-3. Biphasic recruitment of the RAP80 complex to ICL lesions is dependent
on PARP1 and ubiquitination.
(A, B) Representative images and quantification of MERIT40 at laser induced psoralen
crosslinks in HeLa cells. Crosslinking experiments were performed at 48 hours after
transfection with the indicated siRNAs. The arrows depict positive recruitment signals.
Three independent experiments were conducted.
(C) Representative images of EYFP-RAP80 and a mutant lacking the first UIM domain
at 5 minutes after laser induced psoralen crosslinking.
(D) Live imaging of EYFP-RAP80 and RAP80 mutant recruitment to psoralen
crosslinking.
(E) GFP-tagged RAP80 protein was recruited to psoralen-induced ICLs at various time
points after laser activation in HeLa cells. PARP inhibitors Olaparib (5mM) and NU1025
(500mM) were added to the cells at 1 hour prior to ICL damage induction.
(F) Quantification of mean intensity of recruitment signals at each time point after laser
induction of ICL was quantified.
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Figure 2-4. Merit40 mutation reduces ICL unhooking efficiency and HR repair of
ICL damage.
(A, B) Representative image and quantification of RAP80 and FANCD2 at laser induced
psoralen crosslinks in HeLa cells. The arrows indicate positive recruitment signals.
(C) Cells were treated for 1 hour with 50mM cisplatin followed by cisplatin removal.
Samples were taken at different time point post cisplatin treatment and unhooking of ICL
was measured using a modified comet assay (please see methods for a detailed
description). Immediately before analysis, cells collected from different time points were
exposed to 12.5Gy IR. DNA interstrand crosslinking was expressed as percentage
decrease in tail moment compared to irradiated controls calculated by the formula: %
decrease in Olive tail moment=[1−(TMdi−TMcu)/(TMci−TMcu)]x100; where TMdi = tail
moment of cisplatin-treated irradiated sample; TMcu = tail moment of untreated,
unirradiated control; TMci = tail moment of untreated, irradiated control.
(D) MEFs were labeled with BrdU for 2 cell cycles and then treated with 20ng/ml MMC
for the last 24h prior to harvesting for metaphase analysis of SCEs. Quantification was
derived from 4 independent experiments.
(E-G) HeLa cells depleted of MERIT40 by three individual siRNAs show reduced
recruitment of BRCA1 (E), Rad51 (F), and RPA (G) to psoralen-induced ICLs. Mean
intensity of protein co-localized to ICL stripes were quantified in single cells at 20min
after laser treatment.
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Figure 2-5. Combined Merit40 and FancD2 deficiency in mice does not increase
genomic instability in response to MMC.
(A) WT, M40, FANCD2 knockout (FD2), and M40, FD2 double knockout MEFs were
exposed to the indicated doses of MMC and survival was assessed by clonogenic assay in
2 independent experiments, in each experiment, 6 repeats were analyzed at each drug
concentration for each genotype.
(B) Chromosome abnormalities were quantified in MEFs derived from WT, M40, FD2
and M40 FD2 mice. Chromosomal abnormalities per metaphase, including chromatid and
chromosomal breaks (breaks) and radial chromosomes (radials) were quantified in 3
independent experiments. (n>100 metaphases/genotype)
(C, D) Representative image and quantification of RPA recruitment to laser induced
psoralen crosslinks. Mean intensity of protein co-localized to ICL stripes was quantified
in single cells at 10 min after laser treatment. Scale bar: 7mm.
(E) Sister chromatid exchanges were quantified in WT, M40, FD2 and M40 FD2 MEFs
treated with 20ng/ml MMC for 24 hours. Student’s t tests in this panel were performed
between FD2 and M40 FD2 cells.
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Figure 2-6. Cooperative genetic interactions occur between MERIT40 and BRCA2
in response to ICL damage.
(A, B) Plating efficiency of WT, M40, two clones of inducible BRCA2f/fCre-ERT2 (B2A
and B2B) and three clones of inducible MERIT40 BRCA2f/fCre-ERT2 MEFs (M40B2A,
M40B2B, M40B2C). MEFs were treated with 500nM 4-hydroxytamoxifen (4-OHT) for
48h and then plated at 500 cells per 60mm plate. Crystal violet stained colonies were
counted 10 days after plating. Student’s t tests were performed between WT and M40A;
and also between B2A and three clones of M40 B2 MEFs.
(C) WT, M40, B2f/fCre-ERT2, M40 B2f/fCre-ERT2 MEFs were treated with 4-OHT for
48h to induce BRCA2 incision. Cells were then treated with 20ng/ml MMC for an
additional 24h prior to metaphase harvest. (n>100 metaphases/genotype). Student’s t tests
were performed between B2 and M40 B2 cells.
(D) MEFs were incubated with 4-OHT for 48h to induce BRCA2 incision, then treated as
in Fig. 4D. Student’s t tests were performed between B2 and M40 B2 cells and
quantification was derived from 4 independent experiments.
(E) Loss of DNA2 exacerbates levels of chromosomal abnormalities in M40 B2 MEFs.
Two independent experiments were conducted with two different siRNAs. The data for
siDNA2-1 is in supplementary Figure 10A.
(F) SCEs were analyzed for the indicated cells. Student’s t tests were performed between
M40 B2 siCtrl and M40 B2 siDNA2-2. Two independent experiments were conducted.
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Figure 2-7. Model for contributions of MERIT40 to ICL repair.
MERIT40 utilizes PAR and ubiquitination to rapidly recognize ICL damage prior to
FANCD2. Merit40-/- cells have delayed unhooking, coupled with reduced end resection
and homologous recombination in response to ICLs. Merit40 deficiency exacerbates
genomic instability in BRCA2 mutant cells, but not in the context of FANCD2 mutation.

51

Figure S2-1
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Figure S2-1. Basic characterization of Merit40 deficient mice and MEF cells.
(A) Schematic illustrating the gene trap strategy used to disrupt MERIT40 locus.
Translated exons are represented as grey boxes and non-coding exons are displayed as
white boxes. The Omnibank Gene Trap Vector 76 is inserted in intron 1. SA: splicing
acceptor site, BGEO: beta-galactosidase, pA: poly-A, LTR: Long Terminal Repeat.
(B) Protein expression levels in MEFs. Expression levels of MERIT40 protein and its
partners were evaluated by western blotting, using Tubulin for normalization. * Nonspecific band recognized by MERIT40 antibody.
(C) GroWTh curve of primary MEFs. Experiments were repeated for three times.
(D) MEFs were collected 2h after exposure to 0 or 2Gy IR and mitotic cell number was
quantified. Three independent experiments were conducted.
(E, F) WT, M40 and RAP80-/- (R80) cells were collected at 8h post 10Gy IR, and cells
with >5 RAP80 foci were quantified in (F) in three independent experiments. R80 cells
serve as a positive control.
(G, H) MEFs were exposed to no damage in (G) (spontaneous breaks) and 10Gy
irradiation and collected 24h after IR in (H) (persistent breaks). Mean fluorescence
intensity (MFI) of g-H2AX staining was quantified. In this panel, significance was
analyzed with two-tailed paired Student’s t test; * P<0.05, *** P<0.001.
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Figure S2-2
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Figure S2-2. Merit40 deficient mice and MEF cells are hypersensitive to MMC.
(A) U2OS cells with knockdown of MERIT40 or Abraxas displayed reduced survival to
escalating doses of MMC as assessed by colonogenic assay. Two individual siRNAs
were used towards MERIT40 as well as Abraxas.
(B, C) MEFs (B) and splenocytes (C) were treated with 20ng/ml MMC for 24h and then
harvested for chromosomal analysis from metaphase spreads. Breaks include chromatid
and chromosomal breaks. Quantification was derived from 3 independent experiments.
(D) TUNEL positive cells were quantified by counting 4 fields per mouse and three mice
per genotype at Day 6 and Day 9 post MMC.
(E) Histological appearance of tissues from mice after one-time intraperitoneal injection
of 12mg/kg MMC. Hematoxylin-eosin stained sections of tissues from WT (upper) and
M40 (bottom) mice at Day 9 (×40). Scale Bar: 500mm
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Figure S2-3
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Figure S2-3. RAP80 complex is essential for repairing various S phase DNA
damaging agents.
(A, B) WT and M40 MEFs (A) or MCF10A cells with knockdown of different members
of RAP80 complex (B) were treated with Aphidocolin (APH) for 6 hours and FACS
analysis was conducted as described in Figure 2A to detect restart efficiency.
(C-F) Cell proliferation assay was performed to study the survival of WT and M40 MEFs
in presence of indicated agents.
(G) MEFs were treated with 400mM HU for 24h and then harvested for chromosomal
analysis. Quantification was derived from 2 independent experiments.
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Figure S2-4
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Figure S2-4. Kiaa0157 deficiency does not sensitize cells or mice to DNA damaging
agents.
(A, B) BRCA1 and RAP80 are recruited to IR-induced foci similarly in KIAA0157-/- and
WT MEFs at 8h post 10Gy IR.
(C, D) KIAA0157-/- mice do not show hypersensitivity to either IR (C) or MMC (D).
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Figure S2-5
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Figure S2-5. RNF8 and RNF168 are essential for RAP80 complex recruitment to
MMC induced foci sites, but not FANCD2.
(A, B) Recruitment of FANCD2 and MERIT40 to MMC foci in U2OS cells. Following
knockdown of RNF8 or RNF168, cells were treated with 500ng/ml MMC for an
additional 24h prior to immunofluorescence. Three independent experiments were
conducted.
(C) GFP tagged RAP80 protein did not show localization to laser damage site in the
absence of psoralen.
(D, E) GFP-tagged RAP80 protein was assessed for recruited to psoralen-induced ICLs at
various time points after laser activation in cells that had been transfected with siRNA to
either RNF8 or RNF168 72h prior to ICL induction. Scale bar: 3.2mM
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Figure S2-6
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Figure S2-6. MERIT40 is not responsible for FANCD2 recruitment to ICL sites.
(A) Mcherry-tagged RAP80 protein and GFP-tagged FANCD2 were assessed for
recruitment to psoralen-induced ICLs at various time points after laser activation in PD20 cells.
(B) Quantification of mean fluorescence intensity at each time point after laser induction
of ICL.
(C, D) Representative images and quantification of FANCD2 at laser induced psoralen
crosslinks in HeLa cells 20min post activation.
(E) Splenocytes were isolated from WT and MERIT40 deficient mice. Cells were treated
with 100ng/ml MMC for 4h or 24h, and FANCD2 mono-ubiqutination was assessed.
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Figure S2-7
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Figure S2-7. MERIT40 is essential for RAD51 and RPA recruitment to MMC sites
and MERIT40 regulates end resection differently in response to DSBs and ICLs.
(A) Representative image of SCEs after 24h 20ng/ml MMC treatment in WT and M40
MEFs.
(B-D) Representative image of BRCA1 (B), Rad51 (C) and RPA (D) recruitment to
psoralen crosslinks with control siRNA or MERIT40 siRNA in HeLa cells. Three
independent experiments were conducted.
(E) Immunoblot for phosphorylated RPA (p-RPA32) was performed in WT and Merit40/-

MEFs at 24 hour after treatment with 500ng/ml MMC. Numbers below p-RPA bands

represent the quantification of band intensities normalized to Tubulin.
(F) Western blot showing MERIT40 expression in U2OS cells with two different siRNA
towards MERIT40. Tubulin was used as loading control.
(G) U2OS cells were treated with RNF8 and RNF168 siRNA for 48h and then with
500ng/ml MMC for additional 24h. Mean intensity per nucleus was quantified using
ImageJ and three independent experiments were performed.
(H) MEFs were labeled with BrdU for 2 cell cycles in total and cells were treated with
1mM Etoposide in the last 5h.
(I, J) Flow cytometry showing BrdU immunofluorescence in splenocytes 2h following
30Gy irradiation. Cells where stained for BrdU in non-denaturing conditions to check end
resection level and cell cycle stage was determined by staining with DNA-binding dye,
67

propidium iodide (PI). Increased BrdU signal indicates higher level of end resected DSB
breaks. (J) Quantification of BrdU signal in S/G2 phase of cell cycle (upper right corner
in I) from three independent experiments.
(K) Cell cycle distribution of WT and M40 splenocytes as measured by PI staining.
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Figure S2-8
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Figure S2-8. Dna2 mutation rescued chromosomal abnormality in Fancd2 deficient
cells, but not cell survival in response to MMC.
(A) Chromosome abnormalities were quantified in splenocytes derived from WT, M40,
FD2 and M40 FD2 mice. Chromosomal abnormalities per metaphase, including
chromatid and chromosomal breaks (breaks) and radial chromosomes (radials) were
quantified in 3 independent experiments. (n>100 metaphases/genotype)
(B) Cells with the indicated genotypes were treated with siRNA for 48h and 20ng/ml
MMC was added for 24h prior to metaphase harvest. Loss of DNA2 rescues
chromosomal abnormalities in FD2 cells,
(C) Loss of DNA2 did not rescue cell survival ability of FANCD2 deficient MEFs in
response to MMC. FANCD2 cells were treated with control siRNA or siDNA2 for 48h
and then cells were plated and treated with escalating doses of MMC. Cell survival was
examined by MTT assay 3 days post MMC treatment. Two independent experiments
were conducted.
(D) Further reduction of cell survival upon knockdown of DNA2 in Merit40-/- MEFs was
assessed by colonogenic assay. Student’s t tests were performed for Merit40-/- MEFs
between siCtrl and siDNA2 group at the same drug dose. Three independent experiments
were conducted, 6 repeats were analyzed at each drug concentration for each genotype.
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Figure S2-9. MERIT40 and BRCA2 cooperated to resolve MMC induced ICLs.
(A) Representative image of chromosomal abnormalities in M40, B2 and M40 B2 null
splenocytes.
(B) Genomic DNA level of BRCA2 in WT, M40, B2, M40 B2 splenocytes after 48h of
500nM 4-OHT treatment. This indicates the average excision rate of BRCA2 in
splenocytes from two mice for each genotype.
(C) WT, M40, B2f/fCre-ERT2, M40 B2f/fCre-ERT2 splenocytes were treated with 4-OHT
for 48h to induce BRCA2 incision. Cells were then treated with 20ng/ml MMC for an
additional 24h prior to metaphase harvest. (n>100 metaphases/genotype). Student’s t tests
were performed between B2 and M40 B2 cells.
(D) CAPAN-1 cells were treated with control siRNA or siRNA towards MERIT40,
RAP80 and Abraxas for 48h and then 20ng/ml MMC for additional 24h. Student’s t tests
were performed between cells treated with control and MERIT40 siRNA, Abraxas
siRNA, or RAP80 siRNA.
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Figure S2-10
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Figure S2-10. Nucleases DNA2 and CtIP contributed to ICL repair in Merit40-/Brca2-/- deficient cells.
(A) A different siRNA towards DNA2 demonstrates the same genetic interaction between
MERIT40, BRCA2 and DNA2 as that in Fig. 6 E.
(B) Loss of ExoI in MERIT40 deficient cells exacerbates chromosome abnormalities,
indicating that MERIT40 and ExoI are not epistatic in resolving ICLs.
(C) Loss of CtIP increases chromosomal aberrations in M40 B2 deficient cells, indicating
CtIP plays an important role in resolving ICL damage upon loss of both MERIT40 and
BRCA2.
(D) Loss of MMEJ pathway protein, Lig3 or POLQ, didn’t further increase chromosomal
aberrations in M40 B2 deficient cells.
(E) Traffic light reporter (TLR) was used to study the role of MERIT40 protein in MMEJ
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. Mcherry positive signal indicates successful repair of double stranded breaks by

MMEJ pathway.
(F) siRNA knockdown efficiency in MEFs as indicated. The knockdown efficiency of the
targeting genes was examined by RT-qPCR.
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CHAPTER 3. BRCC36 Deubiquitinating Activity Regulates an Auto-Inhibitory
Switch in BRCA1-RAP80 Double Strand Break Recognition.

I.

Introduction

The RAP80 complex consists of five stoichiometric members, RAP80, BRCC45,
BRCC36, Abraxas and MERIT40, that are collectively required to target BRCA1 to DNA
damage sites. RAP80 has tandem ubiquitin interacting motifs (UIMs) that bind lysine63
(K63)-linked polyubiquitin chain specifically, while BRCC36 is a K63-Ub specific
deubiquitinating enzyme (DUB) and this enzymatic activity requires interactions with
other members of the RAP80 complex83. A recent study between the Greenberg and
Sicheri labs revealed the structural basis underlying BRCC36 activation by interaction
with KIAA0157, a binding partner of BRCC36 in a cytoplasmic complex that shares
similar complex members with the RAP80 complex. This study also demonstrated that
rationally designed point mutations from structural analyses at either E33A or H122Q
and H124Q (QSQ) could abolish the enzymatic activity of BRCC3684. E33A is an
inactive mutant that retains BRCC36 active site structure, while QSQ results in distortion
of the BRCC36 active site.

Our previous study showed that loss of MERIT40 sensitizes cells to ICL inducing
agent27. As the stability of the RAP80 complex is disrupted in Merit40-/- cells, it is
unclear which RAP80 complex activity, targeting BRCA1 to damage sites or DUB
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activity, is responsible for ICL repair. Moreover, loss of MERIT40 sensitizes Brca2
mutant cells to the chemotherapeutic agent MMC, warranting further investigation into
whether disrupting the RAP80 complex can be exploited in Brca2 mutant cells. For drug
development, a protein with enzymatic activity is often preferable. In the RAP80
complex, BRCC36 is a great candidate as its enzymatic activity could potentially be
targeted. Disruption of the RAP80 complex is well tolerated in mice19,27,28,63, suggesting
this pathway could be manipulated to selectively kill Brca2 mutant cancer cells.

RAP80-BRCC36 was previously shown to reverse RNF8-dependent ubiquitination
events at DSBs. BRCC36 deficiency can partially rescue sensitivity of RNF8 deficient
cells to IR, indicating the importance of ubiquitin signaling reactions at DNA damage
sites85. To understand how DUB activity contributes to the DNA damage response in a
physiologic setting, we adapted CRISPR/Cas9 technology to generate knock-in mice
harboring E33A, or QSQ DUB inactive BRCC36 mutants at the endogenous locus. We
found that DUB inactive cells demonstrated similar DNA repair defects to Merit40-/cells. Importantly, DUB inhibition sensitized BRCA2 mutant cells to MMC,
demonstrating that cooperation between the RAP80 complex and BRCA2 in resolving
ICL damage depends on DUB activity. Mechanistically, deubiquitination of RAP80 by
BRCC36 is essential for efficient binding of the RAP80 complex to the chromatin,
suggesting an auto-inhibitory mechanism entailing RAP80 ubiquitination regulates
BRCA1-RAP80 localization to DNA damage sites and DNA repair function.
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II.

BRCC36 DUB activity is partially responsible for RAP80 dependent DNA
damage response function

To determine the functional role of DUB activity in DNA damage responses in an in vivo
system, Brcc36E33A/E33A and Brcc36QSQ/QSQ knock-in mice were generated (Fig. 3-1A).
Brcc36KO/KO mice were produced at the same time as a control for complete loss of the
complex. Upon intercrossing heterozygous mutant animals (Brcc36E33A/+, Brcc36KO/+ or
Brcc36QSQ/+), we obtained homozygous mutant pups Brcc36E33A/E33A, Brcc36KO/KO or
Brcc36QSQ/QSQ) at the expected Mendelian ratio (~25%). DUB inactive BRCC36 mice
were fertile and no obvious defects were observed. Meanwhile, the cell cycle profile of
primary splenocytes demonstrated that BRCC36 mutant or knockout mice proliferated at
a similar rate as the wildtype (WT) cells (Fig. 3-1B), further supporting the idea that loss
of BRCC36 or inactivation of DUB activity is well tolerated in the mice. We were able to
recapitulate most of our prior findings in Merit40 null MEFs in DUB inactive MEF cells.
Specifically, Brcc36QSQ/QSQ mutant cells have reduced BRCA1 and MERIT40 foci
formation following ionizing radiation (Fig. 3-1C,D). Although DUB mutant cells did not
show significant sensitivity to MMC by clonogenic assay (Fig. 3-1E), they had elevated
levels of chromosome instability in response to ICLs, but not to PARP inhibitor (PARPi)
(Fig. 3-2F). Additionally, these cells showed delayed recovery in response to S phase
damage (Fig. 3-1F, G), indicating DUB activity is essential for replication restart under
replication stress. Our data indicates that DUB activity is similar, albeit less severe to loss
of ubiquitin recognition in Merit40-/- cells with respect to DNA repair.
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III.

DUB inhibition sensitizes BRCA2 mutant cells to ICL inducing agents.

Loss of MERIT40 was shown to exacerbate defects in Brca2 mutant cells phenotypically,
however, it was unclear which activity of the RAP80 complex is disrupted when losing
MERIT40. To further understand whether DUB inactivation is able to sensitize Brca2
mutant cells to MMC to the same extent as destabilization of the RAP80 complex in vivo,
we exploited a Brca2 mutant mouse model, in which exon27 of BRCA2 was deleted.
These mice were viable, despite infertility in males and a shorter life span due to elevated
rates of cancer. Brca2Δ27/Δ27 mice lack a C-terminal RAD51 binding domain and
demonstrate defective RAD51 localization to DNA damage sites, hypersensitivity to
ICLs, as well as defective replication fork protection ability86-88. This mouse model
provides us an opportunity to study mouse physiology as well as spontaneous disease
progression. Therefore, we crossed Brcc36E33A/E33A, Brcc36QSQ/QSQ as well as Brcc36KO/KO
with Brca2Δ27/Δ27 to generate double mutant mice.

Brcc36E33A/E33A Brca2Δ27/Δ27 and

Brcc36KO/KO Brca2Δ27/Δ27 mice were generated at a significant lower ratio than mendelian
ratio. However, Brcc36QSQ/QSQ Brca2Δ27/Δ27 were generated at a similar ratio as expected
(Fig. 3-2A). Further reduced lifespan was observed in all combinations of Brcc36 and
Brca2 mutation, indicating DUB inhibition exacerbates genome stability abnormalities in
Brca2Δ27/Δ27 mice.
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The plating efficiency in three clones of double mutant MEF cells was significantly lower
when compared to two isogenic clones of Brca2Δ27/Δ27 MEF cells (Fig. 3-2C). The effect
is not attributed to further loss of fork protection ability in double mutant cells (Fig. 32D). Instead, increased genome instability was observed as measured by cytogenetic
aberrations in response to ICLs (Fig. 3-2E, F). Taken together, these results suggest that
BRCC36 cooperates with BRCA2 to resolve ICLs partially via its DUB activity.

IV.

Deubiquitination of RAP80 depends on BRCC36 DUB activity

Consistent with previous studies89, protein level of the RAP80 complex member Abraxas
did not change in BRCC36 DUB inactive cells, indicating the RAP80 complex was not
destabilized upon DUB inactivation. Surprisingly, from three independent isogenic MEF
groups, reduced RAP80 band intensity was observed in DUB mutant cells in comparison
to WT MEFs (Fig. 3-3A). To rule out the possibility that the difference observed was due
to variation in cell lines, WT and E33A BRCC36 cDNAs were introduced in the
Brcc36KO/KO MEFs. Consistently, reduced RAP80 band intensity was observed in cells
expressing the E33A mutant of BRCC36. Because other RAP80 complex members were
not destabilized, it is unlikely that the RAP80 protein itself is being degraded in DUB
inactive cells. An alternative explanation could be that the RAP80 protein is being highly
modified by ubiquitination upon DUB inactivation, rendering the unmodified version of
RAP80 hard to visualize. It is likely that in DUB inactive cells, unmodified RAP80 is
very minimal and below the detection threshold of the antibody, which leads to the
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observation of reduced unmodified RAP80 band intensity. Previous studies provide
supporting evidence of this hypothesis as in HeLa S3 cell line with overexpressed DUB
inactive BRCC36, RAP80 was shown to by modified by ubiquitination at multiple lysine
sites by mass spectrometry (MS). Additionally, K63-linked ubiquitination was also
detected in MS analysis, suggesting that RAP80 is modified by K63-linked ubiquitination
at multiple lysine sites83 and the deubiquitination of RAP80 is dependent on BRCC36
DUB activity.

To test this hypothesis, TUBE (tandem ubiquitin binding entity) pull down coupled with
DUB treatment was employed to quantitatively evaluate the ubiquitination level of
RAP80 in vivo. After all the ubiquitinated protein was immunoprecipitated by the TUBE,
they were treated with a linkage specific DUB. An increased signal for the less modified
RAP80 protein upon K63 specific DUB AMSH treatment indicated that RAP80 was
modified by K63-linked ubiquitination. Additionally, treatment by the non-specific DUB
USP2 led to a greater increase in RAP80 protein, suggesting RAP80 was highly modified
by ubiquitination, in agreement with a recent study that shows RAP80 is ubiquitinated in
steady state90. When comparing WT and E33A cells, a more intense RAP80 band was
observed in E33A than WT cells, supporting the idea that BRCC36 regulates
deubiquitination of RAP80. Interestingly, an increase in the RAP80 band intensity was
observed in response to DNA damage (Fig. 3-3C-E), suggesting that ubiquitination of
RAP80 increased upon DNA damage and deubiquitination of RAP80 both at steady state
as well as in response to DNA damage depended on BRCC36. Additionally, BRCC36
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was also able to deubiquitinate itself. Similar results were observed when we examined
the ubiquitination level of RAP80 in Brcc36-/- HeLa S3 cell lines with different forms of
BRCC36 being reconstituted to a similar level as endogenous BRCC36. In line with the
results in MEFs, deubiquitination of RAP80 and BRCC36 is mediated by BRCC36 (Fig.
3-3F). Notably, the effect of E33A mutant was stronger than QSQ mutant of BRCC36,
which might explain the differences in observed phenotypes in corresponding mice in
Fig. 3-2A. Taken together, these results support the idea that RAP80 and BRCC36 are
deubiquitinated by BRCC36 and this deubiquitination event might be essential for
chromatin localization of the RAP80 complex, as Brcc36E33A/E33A cells had reduced
chromatin association of RAP80 complex in response to IR (Fig. 3-3G).

V.

Discussion

It is well established that ubiquitin chain synthesis and turnover are essential for DNA
repair processes. In response to DSBs, ubiquitination on nucleosomes flanking DNA
damage sites was rapidly established and this platform was critical for recruiting
numerous downstream signaling and machinery DNA repair proteins91. Ubiquitin E3
ligases could either function to generate modifications that allow downstream signaling
protein binding, or regulating essential repair proteins directly. E3 ligases such as RNF8
and RNF168 were known to catalyze K63-linked ubiquitin synthesis on H1 and H2A
35,50

, in addition, HECT domain ubiquitin E3 ligases TRIP12 and UBR5 restricted the

spreading of ubiquitination chain on the chromatin by regulating RNF168 to avoid
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potential deleterious consequences92. Less is known about how DUBs mediate DNA
repair. DUBs are able to reverse ubiquitin synthesis completely as well as edit the
topology of ubiquitin linkage. It is unclear which DUB activity, contradicting E3s
directly or ensuring efficient ubiquitin cycling, is essential for DNA repair process. To
examine the physiological importance of the DUB activity of BRCC36, we knocked in
BRCC36 with point mutations at endogenous locus that abolish its DUB activity, but not
disrupt the stability of the RAP80 complex. This knockin genetic model provides a great
system to determine the physiological importance of DUB activity.

DUB inactive mice BRCC36E33A/E33A displayed more severe phenotype than
BRCC36QSQ/QSQ. It is still unclear what accounts for this difference as both mutants
abolish the DUB activity of BRCC36. From structural analysis, point mutation at E33 site
generates a mutant form of BRCC36 that more closely mimics active site configuration,
as the structure is less distorted and local sites were more preserved in comparison to
QSQ. These features could potentially account for the observed differences. Nonetheless,
both mutants showed similar reductions in RAP80 complex DNA damage response
functions.

The cytogenetic analysis demonstrated that DUB mutant cells experienced elevated
genome instability in response to MMC, suggesting a defect of ICL repair in DUB
mutant cells. The kinetics of the RAP80 complex localization to proralen induced ICLs
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should be determined via similar approach as in Chapter 2. Additionally, the biochemical
analysis in study was conducted following IR-induced DSBs, instead of ICL-induced
DNA damage. Whether BRCC36 dependent RAP80 deubiquitination works in a similar
approach in response to ICLs to DSBs should also be examined.

RAP80 is highly ubiquitinated at steady state as well as in response to DNA damage;
implicating specific E3 ligases that regulate the ubiquitination of RAP80 could
antagonize BRCC36 and affect RAP80-BRCA1 chromatin localization. Therefore, efforts
should be made to determine the E3 ligases, which could potentially BRCA1 chromatin
localization at DNA damage sites.

As BRCC36 and RAP80 form a complex in stoichiometric ratio, and previous studies
suggested that RAP80 and BRCC36 demonstrated a faster and more dynamic exchange at
DNA damage when compared to Abraxas or BRCA193, deubiquitination of RAP80 and
BRCC36 might facilitate this dynamic exchange of these two proteins at DNA damage
sites. Additional experiments are required to determine whether rate of RAP80 exchange
at DNA damage sites is reduced in BRC36E33A/E33A cells when compared to WT cells. If
the RAP80 exchange rate were affected by DUB activity of BRCC36, a novel mechanism
of ubiquitination regulation would be demonstrated for the first time at DNA damage
sites to mediate efficient DNA repair.
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VI.

Experimental Procedures

For the experiments that were also conducted in the previous project, the details could be
found in the experimental procedures section in Chapter 2.

Mice. BRCC36E33A/E33A and BRCC36QSQ/QSQ knockin mice were generated via
CRISPR/Cas9 technology. HR template oligos were listed as follows: BRCC36E33A/E33A:
5’GAGTCTGACGCTTTCCTAGTTTGTCTCAACCATGCTCTGAGCACAGAAAAGGA
GGCAGTGATGGGTCTGTGTATAGGCGAGGTAAGTTGGCCACCTTGGCTGAAA
TCTTGCTGATCAATACCCTGTGTTCCTGGAGGCGGCTGGG-3’. BRCC36QSQ/QSQ:
5’CTTGACAAACATACAGGTTGGCTGAACTAACAGGTCGTCCCATGAGAGTTGT
TGGCTGGTATCAGTCACAACCTCATATAACTGTTTGGCCTTCACATGTTGGTA
AGTTTTTATATCATTTCTCCTCCATTACATATCACAGTC-3’. The guide RNA
sequence for these two templates were AGTGATGGGTCTGTGTATAG and
CCAAACAGTTATATGAGGGT respectively. Purified Cas9 mRNAs (100 ng/ul),
gRNAs (100 ng/ul) and oligo DNAs(100 ng/ul) were injected to fertilized eggs from
superovulated B6SJLF1/J females mated with B6SJLF1/J males (from JAX). The
detailed procedures were done according to standard protocol from Penn Transgenic &
Chimeric Mouse Facility. For genotyping, genomic DNA was isolated by first incubated
the mouse-tail with Alkaline lysis reagent (25mM NaOH, 0.2mM EDTA, pH=12) at 95100°C for 1h, then neutralized by Tris-HCL (40mM, pH 5). Brcc36KO/KO mice were also
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generated when producing BRCC36E33A/E33A mice. Specific primers were designed to
only amplify WT or mutant allele at certain temperature by PCR reaction.

E33A group (anneal at 57°C):

:

Forward E33A: GCA GTG ATG GGT CTG TGT ATA G
Forward WT: CTG AGC ACA GAA AAG GAG GA
Reverse: GTT TGA GTT CTT TGC TGG GC
QSQ group (anneal at 57°C):
Forward QSQ: GGT ATC AGT CAC AAC CTC
Forward WT: TGG CTG GTA TCA TTC CCA CC
Reverse: GAG GCA GAA GCA GGC AGA TCT TTC
KO group (anneal at 61°C):
Forward KO: GAA GTG ATG GGT CTG TGT AG
Forward WT: GA AGT GAT GGG TCT GTG TAT AGGG
Reverse: GTT TGA GTT CTT TGC TGG GC
The Brca2Δ27/Δ27 mice were generously provided by Dr. Wei Tong (Philadelphia
Children’s hospital, Philadelphia). Genotyping was performed by PCR on genomic DNA
isolated from mouse tails. Genotyping protocol for Brca2Δ27/Δ27 mice was conducted as
suggested

on

the

website

of

NCI

mouse

repository

(https://ncifrederick.cancer.gov/Lasp/MouseRepository/MouseModels/StrainDetails.aspx
?StrainNum=01XG9&g=Brca2).
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TUBE (Tandem Ubiquitin Binding Entity) pull down. All the experiments were carried
out following the standard manual of Ubitest (UM411, Life Sensors). AMSH and USP2
were incubated with eluted samples for 2h at room temperature.

Cell fractionation. Cells were harvested and incubated with solution A (10mM HEPES,
pH7.9, 10mM KCl, 1.5mM MgCl2, 0.34M sucrose, 10% glycerol, 1mM DTT) with 0.1%
Triton. Cytosolic proteins (S1) were separated from nuclei by centrifugation at 1300g,
5min, 4°C. S1 was further cleared by centrifugation at 20,000g, 10min, 4°C. Nuclei was
washed once in solution A. Nuclei was then lysed in solution B (3mM EDTA, 0.2mM
EGTA, 1mM DTT). Insoluble chromatin was then separated from soluble nuclear
proteins (S2) by centrifugation at 1700g, 5min, 4°C. The final chromatin pellet (P) was
re-suspended in NETN150 buffer (0.5% NP-40, 1 mM EDTA, 20 mM Tris-Cl pH 8, 150
mM NaCl) with 1mM MgCl2 and 0.05U/ul Benzonase (Bimake, B16002) for 30min on
ice. Chromatin fraction was centrifuged at 20,000g, 10min, 4°C to obtain chromatin
bound fraction.

Cell lysis. Whole cell lysates were obtained by lysing cell pellets in cell lysis buffer
(50mM Tris-HCl, pH 7.5, 0.15M NaCl, 1mM EDTA, 1% NP-40, 10% glycerol). No
reducing agents were added to the lysis buffer to minimize activity of DUBs in the lysing
process. 20nM PR619 (LifeSensors Cat. No. SI9619), 10mM NEM, 10mM 1,10-ophenanthroline was added to cell lysis buffer to inhibit DUB activity.
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Antibodies. BRCA1 was detected by IF with a homemade rabbit polyclonal antibody
raised against the exon 11 region of mouse BRCA1 at 1:100. RAP80 (Novus Biologics,
NBP1-87156) was used for IB at 1:100 to in mouse cells and at 1:1000 in human cells.
The following antibodies were used for western blotting for both human and mouse cells.
MERIT40 (Bethyl Laboratory, A302-515A) at 1:1000. Abraxas (Novus Biologics,
NBP1-22977) at 1:1000. BRCC36 (Abcam ab108411) at 1:50,000. GAPDH (Cell
signaling, 2118S) at 1:10,000, Tubulin (Cell signaling 3873S, 1:10,000).

CRISRR/Cas9 knockout. For CRISPR/Cas9 knockout of human BRCC36 in HeLa S3
cells,

the

following

sgRNA

was

TCTAGTTGAACGATGATACA-3’.
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used.

sgBRCC36-1

5’-
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Figure 3-1. BRCC36 DUB activity is essential for BRCA1-A complex IRIF
formation and interstrand crosslink and replication stress response. (A) Sequencing
profiles of Brcc36E33A/E33A (E33A) and Brcc36QSQ/QSQ (QSQ) MEF cells. (B) Cells were
labeled with BrdU for 1h and collected for cell cycle profiling. (C) Representative images
of MEFs of the indicated genotypes at 5h after 6Gy IR. (D) Quantification of foci number
from (C). (E) WT, QSQ or BRCC36KO/KO (KO) MEFs were exposed to the indicated
doses of MMC, and survival was assessed by clonogenic assay in three independent
experiments. In each experiment, three repeats were analyzed at each drug concentration
for each genotype. (F) Schematic of experimental design as well as representative image
of single fiber analysis. (Red tracks) IdU; (green tracks) CldU. Example of a stalled
replication fork and a restarted replication fork was shown. (G) Quantified percentage of
restarted replication forks, which equals to the number of restarted forks divided by the
sum of the stalled forks and restarted forks.
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Figure 3-2. Cooperation between BRCC36 and BRCA2 in response to DNA damage
depends on BRCC36 DUB activity. (A) Non-Mendelian ratio at weaning was observed
in Brca2Δ27/Δ27 Brcc36E33A/E33A, Brca2Δ27/Δ27 Brcc36QSQ/QSQ, and Brca2Δ27/Δ27 Brcc36KO/KO
double mutant mice. (B) Mouse survival curve of Brca2Δ27/Δ27 mice and double mutant
mice. (C) Plating efficiency of two Brca2Δ27/Δ27 MEF clones and three isogenic
Brcc36E33A/E33A Brca2Δ27/Δ27 MEF clones. (D) Fork protection ability of WT,
Brcc36QSQ/QSQ, Brca2Δ27/Δ27 and Brcc36QSQ/QSQ Brca2Δ27/Δ27 splenocytes in response to HU
was examined via fiber labeling. Cells were labeled with IdU and CldU sequentially for
30min respectively, followed by 3h treatment with 4mM HU. (E) Representative picture
of metaphase spread from Brca2Δ27/Δ27 and Brcc36QSQ/QSQ Brca2Δ27/Δ27 cells. (F)
Splenocytes were treated with either 60nM MMC or 1uM PARPi for 24h prior to
metaphase harvest, n>70 metaphases in total from three or more mice per genotype were
analyzed.
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Figure 3-3. Deubiquitination of RAP80 and BRCC36 depends on BRCC36 DUB
activity. (A) RAP80 complex member protein expression level was examined in three
groups of paired WT and mutant MEFs. (B) RAP80 complex members protein
expression level was examined in WT, Brcc36QSQ/QSQ and Brcc36KO/KO cells with
reconstitution of either WT or E33A protein were analyzed for. (C) Schematic of TUBE
pull-down assays. (D, E) MEFs were treated either with no damage or 10Gy IR for 1h.
Cells were harvested and processed according to the schematic of 3C. (F) Knockout of
BRCC36 in HeLa S3 cells was generated via crispr-cas9 technology. WT, E33A or QSQ
BRCC36 protein were reconstituted in BRCC36 KO cells and these cells were subjected
to TUBE pull down without DNA damage treatment (G) WT or E33A cells were treated
with no damage or 10Gy IR for 1h, cytoplasm, nucleoplasm and chromatin bound
fraction were isolated. GAPDH is a marker for cytoplasm fraction and H3 is a marker for
chromatin fraction.
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CHAPTER 4. Global Characterization of Post-Translational Modifications on
53BP1 and RAP80-Bound Mono-nucleosomes via Quantitative Proteomics Analysis

I.

Introduction

Two competitive repair pathways, classical non-homologous end joining (C-NHEJ) and
homologous recombination (HR) ensure accurate and efficient DSB repair in different
cell cycle phases. In Brca1 deficient cells, defective HR repair leads to excessive use of
53BP1-dependent C-NHEJ that produces genomic rearrangement and tumorigenesis.
Concomitant loss of 53BP1 in Brca1 deficient cells allows for end resection and restores
error-free repair by HR48,49, thus largely reducing tumorigenesis as well as genome
instability. This evidence in mice implicates that 53BP1 hyperactivity in Brca1 deficient
cells leads to genesis of genomic instability and cancer susceptibility. The balance
between 53BP1 and BRCA1 signaling has been a hot research area in the field, as
shifting the balance between two repair pathways can be exploited to selectively kill
Brca1 deficient cells.

RAP80 targets BRCA1 to ubiquitin-modified chromatin flanking DSBs, and potentially
could influence the competition between 53BP1 and BRCA1 at DSBs. High-resolution
microscopy has shown that BRCA1 and RAP80 co-localize at DNA damage sites, but not
BRCA1 and 53BP193,94, suggesting that distinct chromatin territories might be recognized
by BRCA1/RAP80 and 53BP1 respectively. These differences also predict that
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nucleosomes associated with RAP80 complex and 53BP1 are likely modified by
differential single or combinatorial histone modifications. Based on electron cryomicroscopy (cryo-EM) structure, 53BP1 binds to multivalent nucleosome modifications,
H4K20Me2 and H2AK15Ub51, and this combinatorial histone code determines 53BP1
protein localization to the chromatin upon DNA damage. Tandem ubiquitin interaction
motifs (UIM) within the RAP80 amino-terminus are essential for RAP80 IRIF formation
and chromatin loading17, indicating that the interaction between RAP80 and chromatin
substrate depends on ubiquitin recognition. However, it is unclear what anchors K63-Ub
chains on the chromatin. The ubiquitinated substrate for RAP80 was suggested to be
histone H2A or H2B, as reduction in RNF8-dependent H2A and H2B ubiquitination
strongly reduces RAP80 chromatin binding. Mass spectrometry (MS) analysis and
biochemical association studies demonstrate that H2A, H2B and RAP80 exist in the same
complex and the interaction between RAP80 and ubiquitinated H2A and H2B increase
dramatically upon DNA damage95. However, it is unknown which lysine sites on H2A or
H2B are modified by ubiquitination to allow recognition by the RAP80 complex, and
whether it is poly-ubiquitination at one lysine substrate or multiple mono-ubiquitination
at several lysine sites on H2A and H2B that are essential for RAP80 recruitment remains
to be determined. It is also possible that substrates other than H2A and H2B mediate
RAP80 localization to damage sites.

Currently, we lack an approach to assess the entire array of modifications on
nucleosomes specifically associated with a given repair protein. Therefore, we set out to
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devise a novel methodology to isolate specific repair protein associated nucleosomes and
quantify histone modifications globally using MS approaches that had previously been
developed by our collaborator, Dr. Ben Garcia. We hypothesize that if we could identify
single or combinatorial modifications that are specifically associated with a certain repair
protein, these modifications could be involved in repair protein recruitment as well as
determine repair pathway choice (e.g. whether a break is repaired by HR or C-NHEJ).
Eventually, this knowledge may allow us to manipulate histone modifications and direct
DNA repair outcome.

Traditionally, western blotting was adopted to characterize histone modifications.
However, there are several limitations to this method, as antibody availability, crossreactivity with adjacent sites, as well as biases due to the presence of co-existing marks,
could all produce misleading results. Therefore, we employed quantitative MS tailored to
histone modifications to discover novel single or combinational histone PTMs. Mononucleosomes associated with specific chromatin binding repair proteins (such as 53BP1
and RAP80) were first isolated and quantitative MS was conducted to assess the full
spectrum of histone modifications on these mono-nucleosomes.

II.

RAP80 and 53BP1 compete to bind to chromatin at DSBs

It has been shown that 53BP1 deficiency leads to a dramatic increase in BRCA1
localization to DSBs and conversely, BRCA1 loss also increases 53BP1 levels at DNA
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damage sites, indicating that BRCA1 and 53BP1 compete for chromatin occupancy52.
Given that 53BP1 foci was found to be more intense in Brcc36 deficient cells (Fig. 4-1A,
B)85 and 53BP1-mediated telomere-telomere fusion events increased from 19.2% to
65.5% when knocking down BRCC3696, a plausible hypothesis is that RAP80 competes
with 53BP1 to bind to ubiquitinated chromatin substrates to mediate distinct DNA repair
events. In agreement, 53BP1 restricted RAP80 foci formation at DSBs as loss of 53BP1
led to more intense RAP80 foci formation (Fig. 4-1C, D). Additionally, concordant with
previous findings, we observed that BRCA1 foci intensity increased significantly in
53bp1 deficient cells and this was partially dampened upon RAP80 depletion (data not
shown). This further supports the hypothesis that competition between 53BP1 and
BRCA1 might be due to compartmentalized chromatin localization of these two proteins.

III.

Establishment and characterization of HeLa S3 cell lines with stably overexpressed eFFR and eAbraxas

The lack of biochemical evidence for different chromatin substrates that mediate the
competition between RAP80 and 53BP1 necessitated our development of a novel
methodology to specifically examine the histone modifications on mono-nucleosomes
associated with RAP80 and 53BP1.

We first established cell lines containing epitope tagged RAP80 or 53BP1 for purification
of these complexes on individual nucleosomes. We had difficulty expressing full-length
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53BP1, possibly due to its large size as well as its importance for downstream signaling.
To circumvent this issue, we decided to overexpress the minimal focus-forming region
(FFR, a.a. 1220-1711) of 53BP1, which contains its oligomerization domain, methyllysine-binding Tudor domains, as well as the ubiquitination-dependent recruitment
(UDR) motif. FFR is the minimal domain structure of 53BP1 that allows it to bind to
chromatin and form DNA damage induced foci97. The lack of N-terminal
phosphorylation sites abolishes its ability to bind to its interacting partner, RIF1 and
PTIP, therefore not affecting downstream signaling events. Additionally, we have
generated point mutation in the Tudor domain and UDR domains within FFR, which
prevents 53BP1 form binding to H4K20Me2 and H2AK15Ub histone modification
respectively. These two mutants serve as negative controls in the experiments as they
have significantly reduced binding ability to chromatin.

For the RAP80 complex, we decided to use another constituent of the complex, Abraxas.
When RAP80 is overexpressed, it interacts with heat shock protein, and does not localize
to DNA damage sites efficiently (data not shown), leading to an increase in background
signal during purification process. Therefore, we decided to overexpress Abraxas for the
following experiments.

Stable lines of HeLa S3 were created by retroviral transduction using a vector encoding
the FFR and Abraxas protein fused to N-terminal Flag and HA epitope tags. This tagged
FFR (eFFR) exhibited co-localization with endogenous 53BP1 after IR in nuclear foci.
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As negative controls, both Tudor mutant and UDR mutant failed to form IRIF, implying
these overexpressed tagged proteins perform in a manner similar to the endogenous
proteins (Fig. 4-2A). This indicates that the system we established recapitulates
endogenous repair protein recruitment and chromatin association.

S phase DNA damage agent-Etoposide, a topoisomerase II inhibitor, was used for the
purification so that both HR and NHEJ machinery are available to process DSBs. As
expected, eFFR and eAbraxas localized to etoposide induced DNA damage sites marked
by γH2AX (Data not shown), thereby this established system gives us an opportunity
purify repair protein bound mono-nucleosomes. In order to generate solubilized mononucleosomes, we first optimized the dose of micrococcal nuclease (MNase) for chromatin
digestion. Based on precise measurement of length of the DNA wrapped around digested
nucleosomes with bioanalyzer (Fig. 4-2B), we successfully isolated mono-nucleosomes,
as the majority of the DNA fragments after MNase digestion ranged from 123bp to 160bp
(~147bp DNA is wrapped about one mono-nucleosome).

IV.

eFFR and eAbraxas bound mono-nucleosome purification

Mono-nucleosomes were then immunopurified with anti-Flag beads (Fig. 4-3A). Silverstained gels demonstrated that eFFR associated with histones; however, the interaction
between the Tudor mutant or UDR mutant of eFFR with histones was significantly
reduced (Fig. 4-3B). This evidence proofed that we are able to specifically isolate DNA
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repair factor-associated mono-nucleosomes via our novel methodology. When examining
eAbraxas bound mono-nucleosomes, we failed to observe interaction between eAbraxas
with mono-nucleosomes, suggesting eAbraxas might have lower affinity for chromatin
than 53BP1, or the interaction might be indirect or transient (data not shown). Therefore,
crosslinking agent formaldehyde was used when upon sample harvesting. In this
condition, eAbraxas was observed to interact with mono-nucleosomes on a silver stain
gel (Fig. 4-3C).

V.

K15 modification is essential for eFFR binding to chromatin.

To identify the PTMs on these repair protein-associated mono-nucleosomes, first, we
employed western blotting to examine whether there are ubiquitinated forms of H2AX
and H2A in these nucleosomes, as 53BP1 is known to bind to ubiquitinated H2A/X at
K15, and the RAP80 complex binds to ubiquitinated substrates. When blotting for
γH2AX, mono-ubiquitinated and di-ubiquitinated γH2AX was observed in eFFR-bound
mono-nucleosomes, but largely reduced in UDR mutant eFFR bound mono-nucleosomes,
indicating that UDR mutant failed to interact with ubiquitinated γH2AX (Fig. 4-3D). A
similar pattern was observed when blotting for H2A (Fig. 4-3E), supporting previous
biochemical data that 53BP1 binds to both H2AX and H2A. Additionally, eAbraxas
bound mono-nucleosomes contained poly-ubiquitinated γH2AX, suggesting ubiquitinated
H2AX could potentially be a chromatin substrate for RAP80 complex.
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However, it is still unclear which lysine site(s) on H2AX is being ubiquitinated,
especially since di-ubiquitinated H2AX was observed in eFFR-bound mono-nucleosomes
and poly-ubiquitinated or potentially multiple mono- or poly-ubiquitinated H2AX were
detected in eAbraxas-bound mono-nucleosomes. To address this question, we established
H2AX KO HeLa S3 cell lines via CRISPR/Cas9 technology. There are four wellcharacterized ubiquitination sites on H2AX, which are K13, K15, K118 and K119. In
order to study the effect of ubiquitination on each lysine site, one or multiple lysine(s) on
H2AX were mutated into arginine to prevent them from being ubiquitinated. These untagged WT, K13R, K15R, K13R/K15R, K118R/K119R, K13R/K15R/K118R/K119R
(K4R) forms of H2AX were stably expressed at a similarly level as endogenous H2AX in
H2AX KO cells (Fig. 4-4B). No 53BP1 foci were observed in H2ax-/- cells, indicating
that H2AX contributes to the initial recruitment of 53BP1. No obvious difference in IRIF
formation was observed in H2AX KO cells when reconstituted with WT versus mutant
H2AX cDNA (Fig. 4-4A). A plausible scenario is when H2AX is phosphorylated,
downstream signaling proteins, such as ubiquitin E3 ligases RNF8 and RNF168,
ubiquitinate the flanking H2A-containing nucleosomes or the other H2A on the same
nucleosome, providing docking sites for 53BP1 binding, and therefore K15 ubiquitination
on H2AX is not essential for retaining 53BP1 at the DNA damage sites. In this model,
H2AX acts in a “seeding” mechanism, and it is only essential for initiating the chromatin
response flanking DSBs.
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To further assess the hypothesis, eFFR was stably over-expressed in all abovementioned
H2AX mutants cell lines. eFFR-associated mono-nucleosomes were immunopurified and
γH2AX was examined to detect ubiquitination level on these damaged mutant
nucleosomes. As expected, reduced amount of di-ubiquitinated and mono-ubiquitinated
H2AX was observed in eFFR-associated K15R nucleosomes. In eFFR-associated K13R
or K118RK119R H2AX mutant nucleosomes, the ratio between ubiquitinated form of
H2AX over non-ubiquitinated form of H2AX was not reduced, indicating in eFFR
associated nucleosomes, K15 is a major site that is being ubiquitinated, but not K13,
K118 or K119 (Fig. 4-4B). In summary, our novel methodology supports previous
studies that, 53BP1 binds to nucleosomes that contain K15 ubiquitination on
H2A/H2AX.

VI.

Quantitative MS Analysis of purified mono-nucleosomes

In an effort to further assess the full spectrum of chromatin modifications that associate
with 53BP1 and the RAP80 complex, we employed MS to quantify histone modifications
in these purified nucleosomes. Due to the weak association between eAbraxas and
nucleosomes, both eFFR and eAbraxas samples were crosslinked with formaldehyde
prior to mono-nucleosome purifications. After silver staining the gel containing these two
samples, gel slices between 6kDa to 28kDa were excised and submitted for MS. Samples
were processed the same way as it was previously described98. Histone ratio was used as
a read out to quantify relative abundance of a specific histone modification to all possible
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modifications on the same peptide. Firstly, we looked at known nucleosome PTMs
associated with 53BP1. As we did not have a positive control for ubiquitination signal for
peptides with a potential ubiquitination site, we lacked confidence in defining an
ubiquitination signal discovery in our dataset. As expected, almost 90% of 53BP1 bound
nucleosomes contained H4K20Me2, when compared to H4K20Me1, in agreement with
previous studies that 53BP1 binds to H4K20Me2 after DNA damage. Conversely,
Abraxas bound nucleosomes are highly enriched for H4K20Me1 (Fig. 4-4C), indicating
methylation at lysine 20 on H4 might direct Abraxas versus 53BP1 binding to chromatin,
then affecting DNA repair pathway choice. Additionally, consistent with prior findings,
H4K16Ac is inhibitory to 53BP1 binding to histone H4K20Me2 peptides52, the histone
ratio of H4K16Ac in 53BP1-bound nucleosome was lower than Abraxas-bound
nucleosomes, again indicating that Abraxas and 53BP1 indeed bind to chromatin areas
with distinct PTMs (Fig. 4-4D).

VII.

Discussion

BRCA1 and 53BP1 are chromatin-associated DNA damage response proteins that dictate
DNA repair mechanism choice. Genetic evidence in mice suggests that a primary
component of BRCA1 function in tumor suppression is to counterbalance 53BP1mediated C-NHEJ, indicating a need to further understand this balance between BRCA1
and 53BP1-mediated signaling pathways.
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This study establishes that the RAP80 complex contributes to the competition between
BRCA1 and 53BP1 chromatin localization. Prior microscopic studies shed light on this
hypothesis by demonstrating that RAP80-BRCA1 and 53BP1 do not co-localize at DNA
damage foci93. In this study, we showed that the RAP80 complex and 53BP1 indeed
compete with each other at DNA damage sites, and we predict that in 53BP1 knockout
cells, eAbraxas binding to nucleosomes would increase. However, these observations in
Fig. 4-1 alone will not address the biochemical basis of this competition. Our newly
developed methods could give more insight into the nature of DSB ubiquitin recognition.

Lack of interaction between the RAP80 complex and the nucleosomes under noncrosslinking conditions suggests that the RAP80 complex might not directly interact with
core nucleosome components. Linker histone H1 was reported to be modified by K63linked ubiquitination in a RNF8-dependent manner50, suggesting H1 could be a potential
chromatin substrate for the RAP80 complex to bind. However, our current methodology
generates mono-nucleosomes, and linker histone H1 was disrupted and not included for
MS analysis. To circumvent this issue, lower dose of MNase could be used to generate
di-nucleosomes or tri-nucleosomes and if histone H1 were essential for RAP80 binding,
stronger interaction between eAbraxas and nucleosomes would be observed.

On the other hand, under crosslinking conditions, Abraxas could interact with
ubiquitinated H2AX-containing nucleosomes. It is unclear which lysine sites on H2AX
104

contribute to this binding. Similar approach as Fig. 4-4B could give more insight into
ubiquitination on which specific lysine site(s) is essential for RAP80 complex binding to
H2AX-containing nucleosomes.

VIII.

Experimental Procedures

Mono-nucleosome preparation. HeLa S3 cells were harvested and washed twice with
PBS. Then cells were resuspended in TM buffer (10mM Tris-HCl, pH7.5; 2mM MgCl2)
with gentle vortexing to a final concentration of 2*107 cells/ml and cells were incubated
on ice for 10min. 10% NP40 was added with gentle vortexing to a final concentration of
1.5% and cell were incubated on ice for additional 5min. Crude nuclei was pelleted by
centrifugation with 1000rcf at 4°C for 5min. After washing twice with PBS, nuclei was
resuspended with TM buffer to 5*107 cells/ml, 1M CaCl2 was added to a final
concentration of 1mM. 0.3U of Mnase (Sigma, N3755-500UN) was added to every 107
cells. These nuclei was incubated at 37°C for 30min with shaking every 5min. Digestion
was stopped by adding EGTA to a final concentration of 2mM. These nuclei was
incubated on ice for 10min. Nuclei was further washed by TM buffer for one time and
nuclei was resuspended with STM600 buffer (10mM Tris-HCl, pH7.5; 2mM MgCl2;
2mM EGTA; 0.1% Triton X-100; 600mM NaCl) for 8h to overnight (O/N). Nuclei were
centrifuged at 20,000 rcf for 10min at 4°C and supernatant contained mono-nucleosomes
and should be collected. If crosslinking was needed, cells upon harvesting were
resuspended in PBS at a concentration of 107 cells/ml. 1% formaldehyde (final
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concentration) was incubated with cells for 8min at rotatory mode at room temperature
(R.T). 25mM Glycine (final concentration) was added to quench the reaction and cells
were incubated for another 5min in rotatory mode at R.T. (All reagents should be kept at
R.T. to ensure high crosslinking efficiency).

Isolate repair protein associated mono-nucleosomes. As mono-nucleosomes were in
solutions containing 600mM NaCl, which was not compatible for Flag pull down
condition. Dialysis was needed to reduce salt concentration in the solutions. Therefore, at
least one hundred times of volume of dialysis buffer (20mM Tris-HCl, pH7.5; 200mM
NaCl; 10% Glycerol (for MS, 5%); 1.5mM MgCl2; 0.1% NP40 (for MS, no NP40), 1mM
DTT) was used compared to mono-nucleosomes containing solution. Dialysis lasted any
time from 6h to overnight at 4°C. Solution was centrifuged at 20,000 rcf for 10min at 4°C
post dialysis. Agarose A/G beads (10ul dry beads for around 1ml supernatant) were used
for pre-clear (2h-O/N, optional step). Mono-nucleosomes were further purified by Flag
agarose beads (7.5ul dry beads for 1mg of protein). For crosslinked samples, Flag
purification step was carried out mostly O/N at 4°C, as the crosslinking process might
block site of contact between Flag beads and Flag tagged protein. Flag agroase beads
were collected and washed with dialysis buffer. Flag peptide was used to elute samples
(Elution buffer: dialysis buffer + Flag peptide). If cells were crosslinked, reverse
crosslinking can be carried out by adding 2* reverse crosslinking buffer (4% SDS,
500mM Tris-HCL pH 8.8, 1M beta-mecaptoethanol).
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Cells and Plasmids. HeLa S3 cells used for purification were grown in suspension. The
following single guide RNA was used. cgH2AX-1 5’-CCTTGCCGCCAGTCTTGCCG3’. H2AX mutants were generated in pMCV Neo Vector. eFFR and eAbarxas were
overexpressed via pOZ-N Flag-HA vector.

107

IX.

Figures

Figure 4-1
B

800000
750000
700000
650000
600000

K

O

W
T

BRCC36 KO

850000

O

Merge

K

DAPI

W
T

γH2AX

Nuclei Itensity (Arbitary Unit)

53BP1

WT

A

30min

2h

D

C
RAP80

FokI

DAPI

Merge

53BP1 KO

WT

RAP80 Foci Intensity

5000
4000
3000
2000
1000

53

bp

1

K

O

W
T

0

108

Figure 4-1. RAP80 and 53BP1 compete to bind to chromatin at DNA damage sites.
(A) Representative images of indicated genotype at 2h post 6Gy IR in WT and
Brcc36KO/KO MEF cells. (B) Quantification of nuclei intensity of A. (C) Schematic of
DSB generation by mCherry-LacI-FokI at an integrated reporter transgene in U2OS cells.
52

. (C) Representative images of indicated genotype at 5h post Shield and 4-OHT

treatment in WT and 53bp1KO/KO U2OS cells. (E) Quantification of foci intensity of (D).
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Figure 4-2. Characterization of HeLa S3 cell line with overexpression of eFFR and
eAbraxas. (A) eFFR, but not TUDOR domain or UDR domain mutants, co-localized
with endogenous 53BP1 at IRIF 2h post 6Gy IR. (B) Analysis of the length of DNA
associated with chromatin by bioanlyzer. The length of the DNA peaked around 123bp160bp, correlating to the length of DNA wrapping around mono-nucleosome (~147bp).
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Figure 4-3. Purified eFFR and eAbraxas-bound mono-nucleosomes demonstrated
differential modifications on γH2AX. (A) Schematic of repair protein associated mononucleosome purification. (B) eFFR associated with mono-nucleosomes were visualized
by silver staining without crosslinking by formaldehyde. In comparison, with similar
amount of bait protein, TUDOR and UDR domain mutants association with chromatin
was largely reduced. (C) Under crosslinking condition, the RAP80 complex member
eBRCC36 and eAbraxas immunoprecipitated with mono-nucleosomes, though their
affinity for mono-nucleosomes was significantly lower than eFFR. (D) eAbraxas and
eFFR were associated with ubiquitinated γH2AX. UDR mutant form of eFFR failed to
interact with ubiquitinated γH2AX. (E) Similar pattern as in (D) was observed when
blotting for H2A instead of γH2AX.
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Figure 4-4. MS analysis identified distinct histone modifications on eFFR and
eAbraxas-bound mono-nucleosomes. (A) H2AX mutants do not affect 53BP1
localization to IRIF. (B) H2AX mutant cells with overexpressed eFFR were established
and examined for the interaction between eFFR and these H2AX mutant-containing
nucleosomes. (C, D) Histone ratio was calculated based on the ratio of intensity of one
specific modification on a peptide to total intensity of all forms of the unmodified and
modified peptides. Quantitative MS was able to identify known histone modifications
that promoted or inhibited eFFR binding to chromatin. Notably, eAbraxas-associated
nucleosomes demonstrated completely different pattern of histone modifications.
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CHAPTER 5. Conclusions and Future Directions
The scope of the present dissertation was to investigate how the RAP80-BRCA1
ubiquitin recognition complex contributes to genome integrity and tumor suppression.
The importance of this work was demonstrated by human genetic studies, which
documented genetic alternation in Abraxas, Rap80 and Merit40 in hereditary breast and
ovarian cancer20,21,79,80, as well as mouse genetic studies, where Abraxas, Rap80 deficient
mice exhibited elevated cancer susceptibility19,28,29. However, the underlying mechanism
of how loss of the RAP80 complex leads to tumorigenesis remained unclear. The work in
this dissertation led to novel insights into the function of the RAP80 complex in vivo.
Genetic studies revealed that the primary function of the RAP80 complex is to mediate
efficient repair of S phase DNA damage, instead of DSBs. Additionally, a novel
regulatory pathway involved DUB activity of the RAP80 complex was uncovered and
this pathway provided an opportunity to inhibit this ubiquitin recognition complex. To
further decipher the chromatin substrates that are essential for RAP80-BRCA1 complex
to localize and inhibitory to 53BP1 binding, we also developed a novel methodology to
purify DNA repair protein associated mono-nucleosomes and analyze full spectrum of
the PTMs on these nucleosomes.

Function of the RAP80 complex in S phase DNA damage response
Generation of Merit40 deficient mice allowed investigation of the primary role of the
RAP80 complex in vivo. Surprisingly, the Merit40-/- mice displayed hypersensitivity to
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ICLs, but not to whole-body irradiation, in contrast to human cells where reduction in cell
survival was shown in cells with knockdown of MERIT40 upon IR treatment. This
variation emphasized the importance of examining a phenotype in various cell line
systems as well as using genetic mouse model to conduct in vivo studies.

We had noted the RAP80 complex was recruited to ICL sites very rapidly. This
immediate localization of the RAP80 complex played an important role in efficient
unhooking of an ICL. Several nucleases have been suggested to process ICL lesions,
including the SLX4 complex and FAN111,55,99-105. Future investigation is warranted as to
if MERIT40 affects their recruitment or activities at ICLs.

Merit40-/- MEFs also displayed difficulty in restarting replication forks after DNA
polymerase stalling, indicating that in addition to ICL repair, the primary role of
MERIT40 function is more broadly applicable to S phase genotoxic stress. Multiple FA
and BRCA pathway proteins have been implicated in replication fork maintenance or
restart68,106,107. The function that MERIT40 exerts in S phase might be through its direct
role in fork restart; or through recruitment of BRCA1, which has been established to
protect replication forks from nucleases68 as well as mediate HR-dependent replication
restart108.
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Several approaches could be utilized to examine the function of MERIT40 in S damage
repair. Firstly, Tus/Ter system could be exploited to examine the functional effect of
MERIT40 loss on replication fork recovery in response to nucleus induced replication
fork stalling108. BRCA1 was shown to promote HR mediated replication fork recovery at
these damage lesions and potentially MERIT40 could function via the same mechanism.
Secondly, to investigate whether MERIT40 has an independent role of BRCA1-RAP80
complex, mice harboring a point mutation at BRCT domain of BRCA1, Brca1S1598F/S1598F,
could be crossed to Merit40 deficient mice. Brca1S1598F/S1598F have defective interaction
with the RAP80 complex, however the mice are still viable109. The double mutant mice
and cells could provide us insights into the function of MRIT40 in mediating ICL repair
and replication fork recovery independent of BRCA1. Lastly, to gain insights into
whether MERIT40 directly affects specific repair protein recruitment or retention at
stalled replication fork, iPOND (isolation of protein on nascent DNA) combined with
mass spectrometry (MS) could be utilized to examine differential protein localization at
stalled replication fork in WT and Merit40 null cells110. Cells would be treated with
aphidicolin or HU to induce replication fork stalling and restart by release form these
agents. In the short release time, nascent synthesized DNA would be labeled with EdU
and CLICK chemistry following EdU labeling would be conducted to allow purification
of proteins on these EdU labeled DNA. MS analysis for these proteins would gain insight
into all differential regulated proteins in WT and Merit40-/- cells and also be informative
about the exact function of MERIT40 protein, whether it affects fork stability during
stalling or it directly recruits replication restart machinery.
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Another intriguing finding in this study is that Merit40-/- and Brca2-/- alleles generated
more than additive increases in genomic instability in response to MMC as well as
strongly reduced cell plating efficiency. Mechanistically, a further reduced HR efficiency
in double knockout cells was observed in the presence of ICL, however, the exact source
of this exacerbated DNA repair deficiency is unclear. End resection level as well as
replication fork restart efficiency could be examined to shed light on this source.
Additionally, iPOND, as discussed in the last paragraph, could also be exploited to
examine the role of MERIT40 in response to replication stress in Brca2 null cells. As the
efficiency of Cre-mediated excision of BRCA2 exon 11 in the mice was low, we failed to
monitor spontaneous disease progression as well as mouse physiology in double mutant
mice. To circumvent this issue, we could either utilize a more robust Cre-ERT2 mouse
strain to cross with Brca2F11/F11, which allows induction of BRCA2 deletion in vivo, or
use another Brca2 mutant mouse model, Brca2Δ27/Δ27, which is viable. Once the double
knockout mice (Merit40-/- Brca2 deficiency) were generated, spontaneous tumorigenesis
could be monitored in both Brca2 mutant mice as well as double knockout mice. Details
of the Brca2Δ27/Δ27 mice as well as double mutant mice will be discussed more in the
following sections. The mouse genetics information would lead to better insight into the
cooperation between MERIT40 and BRCA2 in a physiological system and provide
opportunities for novel therapeutic interventions for Brca2 null tumors.
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BRCC36 Mediated Auto-inhibitory Switch for RAP80
Mouse genetic studies in Chapter 2 intrigued us to explore whether inhibition of the
RAP80 complex would sensitize Brca2 null tumors to chemotherapeutic agent, MMC.
The most druggable target in the RAP80 complex is BRCC36, which is equipped with
enzymatic activity. Therefore, we followed up our study to examine whether BRCC36
DUB inactivation is equivalent to loss of ubiquitin recognition in Merit40-/- cells, as well
as whether DUB inhibition could sensitize Brca2 null cells to ICL-inducing agents.
Indeed, cooperation between DUB inactivation as well as Brca2 deficiency was
observed, shown both by lower than mendelian ratio birth rate and shorter lifespan of the
double knockout mice. However, it is unclear what is the cause of fatality in the double
mutant mice. Age-comparable Brca2 null and Brcc36E33A/E33A or Brcc36QSQ/QSQ Brca2
null mice should be examined for their tissue morphology by H&E staining as well as
apoptosis by TUNEL staining. In addition, we would also determine whether DUB
inhibition accelerates tumor formation in Brca2 null mice.

RAP80 is highly ubiquitinated in response DNA damage, implying one or more E3
ubiquitin ligases might be responsible for inhibitory ubiquitination of RAP80 to reduce
RAP80-BRCA1 chromatin localization. Which E3 ligases are responsible for this process
remains to be investigated. The fact that ubiquitination of RAP80 increases upon DNA
damage suggests the E3 ligases are able to ubiquitinate RAP80 and BRCC36 locally at
the DNA damage site and catalyze K63-linked ubiquitination events. Several E3 ligases
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are known to synthesize ubiquitination in K63-linked topology at DNA damage sites such
as RNF8, RNF16835,50 and RFWD3111. Additionally, E3 ligases that could interact with
RAP80 are also great candidates, including BRCA1. A recent study indicated that E3
ligase TRAIP interacted with a c-terminal region in RAP80 and was required for RAP80
chromatin localization112, suggesting a possibility that TRAIP could counteract with
BRCC36 to regulate RAP80 ubiquitination. Meanwhile, UBC13 is an ubiquitin E2 ligase
that couples RNF8, RNF168 and other E3s to mediate DNA repair process113, therefore
UBC13 might also be involved in counteracting with BRCC36 to regulate RAP80
ubiquitination.

UIM containing proteins could be regulated through an auto-inhibitory mechanism,
where in steady state, the UIM containing protein adopted a closed, auto-inhibited
conformation due to intra-molecular UIM-ubiquitin binding. These proteins are
considered inactive with respect to trans-molecular binding to ubiquitinated target.
Specific DUBs had to remove the ubiquitination to allow the transition from intramolecular UIM-ubiquitin binding to inter-molecular binding114. In this scenario, RAP80
UIM domain might be occupied by intra-molecular binding in steady state to prevent
itself from binding to other ubiquitinated targets. A plausible scenario is that upon DNA
damage, ubiquitination on RAP80 is rapidly removed to allow it binding to ubiquitinated
chromatin targets flanking DNA lesions and BRCC36 DUB activity regulated the
removal of ubiquitination on the RAP80 protein. The experiments listed below will help
to test this hypothetical model. Firstly, whether the binding ability of RAP80 to K63121

linked ubiquitin chain is reduced in BRCC36 DUB inactive cells needs to be examined.
The RAP80 complex could be isolated in WT and Brcc36E33A/E33A cells, then in vitro, we
could determine the ability of the RAP80 complex to bind to non-degradable K63-linked
ubiquitin chain. Secondly, the potential ubiquitination sites should be examined. MS
approach could be exploited to examine RAP80 modifications in WT and Brcc36E33A/E33A
cells. Previous studies from our lab has taken a similar approach and identified potential
ubiquitination sites on RAP80, including K9, K20, K31, K75 and K37483. Most of these
sites were not in close proximity to UIM domain of RAP80 (except K75), suggesting
ubiquitination on these sites might lead to intra-molecular binding to the UIM domain on
RAP80 as well as conformation change in the protein. Lastly, upon identification of the
ubiquitination sites, point mutations on these lysines should be generated at the
endogenous RAP80 locus and test whether the ability of RAP80-BRCA1 recruitment to
DNA damage lesions was restored in Brcc36E33A/E33A cells. In summary, if auto-inhibitory
regulation of RAP80 were proved to regulate the RAP80-BRCA1 chromatin localization,
inhibiting DUB activity of BRCC36 would abolish ubiquitin recognition ability of the
RAP80 complex, thereby affecting BRCA1 chromatin localization.

Characterization of 53BP1- and RAP80-bound chromatin substrates
The competition between 53BP1 and BRCA1 by recruitment analysis via
immunofluorescence demonstrated that they antagonize each other in terms of chromatin
occupancy52. However, it was unclear which BRCA containing complex is primarily
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involved in this competition. This study indicates that 53BP1 and RAP80 compete at
DSBs for chromatin binding. To further characterize the nature of chromatin substrates
for 53BP1 as well as the RAP80 complex, we developed a novel methodology to assess
PTMs on 53BP1 and RAP80 bound nucleosomes via quantitative proteomic analysis.

Preliminary studies uncovered known 53BP1 chromatin substrates, such as H4K20Me2.
Additionally, inhibitory nucleosome PTMs, such as H4K16Ac, was also found depleted
in 53BP1 bound nucleosomes, suggesting our data is robust and reliable. Additional
analysis is needed to understand whether a specific single modification or combinatorial
modifications work cooperatively to create local chromatin environment that favors
recruitment of proteins in one repair pathway over the other repair pathway. The Muir lab
has generated biochemical libraries of histones with specific modifications115. Once the
specific chromatin modifications that are enriched on eAbraxas and eFFR-bound
nucleosomes were established by MS analysis, we could synthesize mono-nucleosomes
with specific modifications to test their binding ability to purified RAP80 complex as
well as 53BP1. In vivo MS analysis combined with in vitro biochemical binding assays
might allow us to decipher the chromatin modification landscape flanking DSB sites.
Additionally, if the enzymes that are essential for a specific modification could be
identified, manipulating the enzymes could allow us to change the kinetics of repair
protein recruitment, direct DNA repair pathway choice and eventually selectively kill
BRCA mutant cancers.
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One caveat in the current MS analysis is the lack of positive control sample for
ubiquitinated peptide at a specific site. RNF168-modified ubiquitinated nucleosome core
particles (NCPs) could be generated in vitro and then processed for MS analysis to give
us a positive control for ubiquitination signal on H2A/X K13 and K15, which might
allow us to quantify ubiquitination signal at K13 and K15 sites for eFFR and eAbraxasbound mono-nucleosomes by MS. Additionally, trypsin generated peptides that cover
K118/K119 sites on H2A(X) or K120 site on H2B are too long for MS analysis,
therefore, alternative proteases could be exploited to generate more suitable length
peptides to allow quantitative analysis by MS.

This dissertation describes a diverse set of experimental strategies to understand the
biology of the RAP80-BRCA1 complex, including generating genetic mouse model to
understand primary function of the RAP80 complex in ICL repair in vivo, exploiting
biochemical analysis to uncover DUB-dependent mechanisms of RAP80-BRCA1
localization to DNA lesions, as well as developing novel methodology coupled with
proteomics to characterize chromatin substrates for RAP80-BRCA1 complex. I hope that
the work presented in this dissertation will provide insight into subsequent studies of
DSB ubiquitin recognition as well as BRCA1 biology.
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